Next Article in Journal
Smokers’ Self-Report and Behavioral Reactivity to Combined Personal Smoking Cues (Proximal + Environment + People): A Pilot Study
Previous Article in Journal
Repetitive Anodal TDCS to the Frontal Cortex Increases the P300 during Working Memory Processing
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Brain Sciences
Volume 12
Issue 11
10.3390/brainsci12111546
brainsci-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Systematic Review

Pharmacological Treatments for Cocaine Craving: What Is the Way Forward? A Systematic Review

by
Dângela Layne Silva Lassi
1,
André Malbergier
1,
André Brooking Negrão
1,
Lígia Florio
1,
João P. De Aquino
2 and
João Maurício Castaldelli-Maia
1,3,4,*
1
Interdisciplinary Group of Alcohol and Drug Studies (GREA), Department and Institute of Psychiatry, Medical School, São Paulo University, São Paulo 05403-010, SP, Brazil
2
Department of Psychiatry, Yale University School of Medicine, New Haven, CT 06510, USA
3
Department of Neuroscience, Medical School, ABC Health University Center, Santo André 09060-870, SP, Brazil
4
Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY 10032, USA
*
Author to whom correspondence should be addressed.
Brain Sci. 2022, 12(11), 1546; https://doi.org/10.3390/brainsci12111546
Submission received: 20 July 2022 / Revised: 1 November 2022 / Accepted: 10 November 2022 / Published: 14 November 2022
(This article belongs to the Section Neuropharmacology and Neuropathology)
Browse Figure
Review Reports Versions Notes

Abstract

:
Background: cocaine craving is a core feature of cocaine use disorder and remains a critical challenge for abstinence and relapse prevention. This review summarizes the anti-craving efficacy of pharmacotherapies tested for cocaine use disorder, in the context of randomized-controlled clinical trials. Objectives: we assessed the databases of the U.S. National Library of Medicine, Google Scholar, and PsycINFO, without date restrictions up to August 2022, to identify relevant studies. Study eligibility criteria, participants, and interventions: we included double-blinded randomized-controlled trials investigating pharmacotherapies for cocaine craving and/or cocaine use disorder whose outcomes included cocaine craving. Study appraisal and synthesis methods: Two authors screened studies’ titles and abstracts for inclusion, and both read all the included studies. We systematically gathered information on the following aspects of each study: title; author(s); year of publication; sample size; mean age; sample characteristics; study set-ting; whether participants were treatment-seeking; study design; craving measures; study interventions; drop-out rates; and other relevant outcomes. Results: Overall, we appraised 130 clinical trials, including 8137 participants. We further considered the drugs from the studies that scored equal to or greater than six points in the quality assessment. There was a correlation between craving and cocaine use outcomes (self-reports, timeline follow-back or urinary benzoylecgonine) in the vast majority of studies. In the short-term treatment, acute phenylalanine-tyrosine depletion, clonidine, fenfluramine, meta-chlorophenylpiperazine (m-CPP) and mecamylamine presented promising effects. In the long term, amphetamine, biperiden, carbamazepine, lisdexamfetamine, lorcaserin, methamphetamine, mirtazapine, pioglitazone, progesterone, guanfacine, levodopa, nefazodone presented promising anti-craving effects. Unfortunately, the highly tested medications were not successful in most of the trials, as follows: propranolol in the short term; amantadine, aripiprazole, bromocriptine, citicoline, ketamine, modafinil, olanzapine, topiramate in the long term. The remaining 52 medications had no positive anti-craving outcomes. Limitations: Our review was limited by high heterogeneity of craving assessments across the studies and by a great range of pharmacotherapies. Further, the majority of the studies considered abstinence and retention in treatment as the main outcomes, whereas craving was a secondary outcome and some of the studies evaluated patients with cocaine use disorder with comorbidities such as opioid or alcohol use disorder, schizophrenia, bipolar disorder or attention deficit hyperactivity. Lastly, most of the studies also included non-pharmacological treatments, such as counseling or psychotherapy. Conclusions: There is a direct association between craving and cocaine use, underscoring craving as an important treatment target for promoting abstinence among persons with cocaine use disorder. Clonidine, fenfluramine and m-CPP showed to be promising medications for cocaine craving in the short-term treatment, and amphetamine, biperiden, carbamazepine, lisdexamfetamine, lorcaserin, methamphetamine, mirtazapine, pioglitazone, progesterone, guanfacine, levodopa, nefazodone in the long-term treatment.

1. Introduction

Cocaine use disorder causes a host of medical, psychological, and social problems worldwide, including cardiovascular disease, infection, violence, and crime. The United Nations Office on Drugs and Crime [1] estimates that, in 2018, 19 million people used cocaine, a number that is expected to grow against the backdrop of the socioeconomic crisis caused by SARS-CoV-2 pandemic. Yet, despite decades of clinical research, thus far no pharmacological treatments for cocaine use disorder have been established. One of the most critical barriers to abstinence and relapse prevention is craving [2], a core symptom of cocaine use disorder, and one whose clinical relevance is underscored by its inclusion as a diagnostic criterion to diagnose stimulant use disorders in the 5th Edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) [3].
At the neurobiological level, prolonged cocaine use can cause brain circuitry modifications and progressively sensitize dopamine systems, leading to recurrent and intense urges—or craving—to use cocaine. Craving is defined as “a more intense, urgent abnormal desire characterized by longing, yearning and physiological need for drug” [4]. The shift from “wanting” to use a drug to “craving” it occurs due to a progressive salience attributed to drug-related stimuli, even when negative cognitions are attributed to drug use itself [5]. Craving can be elicited by cocaine cues—such as paraphernalia and places/situations related to cocaine use—by acute withdrawal, by cocaine, and by stress, which makes feasible to evaluate in a naturalistic way with an ecological momentary assessment or in laboratory studies with the induction of craving.
Distinct biological and psychological mechanisms are believed to contribute to various types of craving [6]. Some evidence indicates that specific types of craving may be particularly amenable to pharmacological interventions, such as the craving for compulsive use in early abstinence [7].
Although the precise pathophysiology of craving remains elusive, some of its neural substrates have been identified, including progressive alterations in limbic, striatal and cortical systems. The amygdala plays a critical role in learning the relationship between significant stimuli and the signals that anticipate them; the anterior cingulate connects to the amygdala and subserves mood regulation and emotional responsivity; the nucleus accumbens mediates the reinforcing properties of cocaine [6]; and the basal ganglia are believed to underlie compulsive component of addiction. Altogether, the shift of cognitive and emotional aspects of cocaine-related memory can lead to compulsive drug-seeking behavior [8].
Converging functional neuroimaging studies involving persons who use cocaine show cue-elicited increases activity in limbic regions, such as the amygdala and anterior cingulate, cerebellum, and prefrontal cortex, as well as decreased activity in subcortical regions, such as the basal ganglia [6,8,9,10]. Another study with positron emission tomography (PET) [9] using personalized cues and autobiographical memories found a decreased activity in the prefrontal cortex, lending support to previous findings showing a disruption of prefrontal activity during craving [4].
Although multiple clinical trials have investigated pharmacological interventions for cocaine use disorder, thus far few of them have included craving as a treatment efficacy outcome. Given the clinical relevance of craving as a potential mediator of return to using cocaine, there is growing interest in studying stimulants, antidepressants, and anticonvulsants as anti-craving pharmacotherapies, as reviewed in recent metanalysis [11,12,13,14].
As craving is strongly associated with compulsive cocaine use [15,16] and is a significant predictor of relapse [2], it is an important treatment target for persons with cocaine use disorder. Hence, we have summarized and appraised findings from randomized trials investigating anti-craving medications for this clinical population. To our knowledge, this is the first systematic review to specifically synthesize and appraise the evidence for anti-craving effects of pharmacological interventions for cocaine use disorder.

2. Methods

2.1. Eligibility

Original pharmacological studies including persons with cocaine abuse or dependence were included in this review if craving was a treatment outcome. Non-original reports such as reviews, meta-analyses, case reports, discussion articles, study protocols; studies that were not randomized, controlled and double-blinded; studies in languages other than English; preclinical studies; studies whose samples was not composed by persons who use cocaine; and studies that did not include craving as a treatment outcome were excluded. Given the variety of nosological classification of cocaine use disorders across the studies included in our review, we use the terms cocaine abuse and dependence interchangeably.

2.2. Information Sources

We searched the databases of the US National Library of Medicine, Google Scholar and PsycINFO up to 1 August 2022 to identify relevant studies.

2.3. Search Strategy

The keywords used in the search were ‘craving’ and ‘cocaine’ and ‘random* controlled Blind*’. The filters used in PubMed and PsycINFO, were ‘clinical trial’ and ‘humans’. The detailed search strategy is included in the Supplementary Materials section.

2.4. Study Selection

First, two authors (D.L.S.L. and J.M.C.M.) read the abstracts of all studies found in the initial search (n = 466). Duplicates (n = 149) and studies that were unrelated to cocaine (n = 77) were excluded. Second, these authors read the remaining studies independently (n = 240). After eligibility were applied, 110 articles were excluded. The remaining 130 studies were included in this review. The present review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Guidelines Checklist [17] for transparent reporting of systematic reviews and meta-analyses, as presented in Figure 1.

2.5. Assessment of Methodological Quality

Two authors, D.L.S.L. and J.M.C.M. independently assessed the risks of bias in each study included, using the Study Quality Guide from the Cochrane Consumers and Communication Review Group [18].

2.6. Data Collection Process

Two authors, D.L.S.L. and J.M.C.M., read all the 130 included studies independently. D.L.S.L. tabulated the data, which J.M.C.M. evaluated. Disagreements between the two authors were resolved by discussion and consensus.

2.7. Data Items

We systematically gathered information on the following aspects of each study: title; author(s); year of publication; sample size; mean age; sample characteristics; study setting; whether participants were treatment-seeking; study design; craving measures; study interventions; drop-out rates; and other relevant outcomes.

3. Results

3.1. Distribution

The included studies ranged from 1987 to 2022. A total of 92% of the studies (120) were conducted in the USA; 2,4% (3) in Brazil; 2,4% (3) in the Netherlands; 0,8% in each of the following Australia (1), Canada(1), France (1) and Mexico (1).

3.2. Participants

Combined, the studies included had 8137 participants; the smallest study had eight participants, whereas the largest had 358 participants. Men comprised the majority (75%) of the sample and 21 studies had only male participants. Conversely, only one study enrolled exclusively women. Seven studies did not report the participant’s gender. The median age was 39 years.
While in 50% of the studies, participants were treatment-seeking, 40% of the studies did not describe participants’ intention to engage in treatment. Approximately 27% of studies included participants who used cocaine through the smoked route; 2% of studies participants who used cocaine intravenously; and 58% of studies included participants who used cocaine through more than one route of administration. Information on the route of administration on the remaining 12% of studies was lacking.

3.3. Assessments

Ninety-three percent of the included studies used the Diagnostic and Statistical Manual of Mental Disorders criteria for cocaine abuse or dependence (20% DSM-III, 71% DSM-IV, 2% DSM-5). The other 7% included criteria from International Classification of Diseases (ICD-10) and unstructured self-report measures.
Craving was assessed by single or multi-factorial craving scales. Approximately 51% of the studies used a Visual Analog Scale (VAS), either alone or in combination with another semi-structured assessments. The most frequent semi-structured assessments were: The Addiction Severity Index (ASI) (39%); the Cocaine Craving Questionnaire (CCQ) (20%); the Brief Substance Craving Scale (BSCS) (20%); the Minnesota Cocaine Craving Scale (MCCS) (16%); and the Cocaine Selective Severity Assessment (CSSA) (12%). These measures are summarized in Table S1, in the Supplementary Materials Section.

3.4. Quality Assessment

The quality assessment was performed using the Study Quality Guide from the Cochrane Consumers and Communication Review Group [18], considering six domains of risk of bias: random sequence generation; allocation concealment; blinding of participants and personnel; blinding of outcome assessment; incomplete data outcome; and selective reporting.
We used a previously established scoring system, in which low risk is indicated by 2 points, unclear risk 1 point, and high risk 0 points, as shown in Table S2, in the Supplementary Materials Section. The scores of the studies included ranged from 2 to 12 points: 85% (111 studies) scored 6 or more (only one scored 12 points, and only one scored 2 points).

3.5. Interventions and Outcomes

Setting: 74%, 21% and 5% of the studies were conducted in the outpatient, inpatient, and hybrid settings, respectively.
Duration of intervention: The duration of the intervention ranged from single-dose/one-day intervention to 16 weeks. The most prevalent duration of intervention was 12 weeks (21% of studies). Most (92%) studies compared a pharmacological agent to placebo, and 8% of studies compared two or more active drugs, directly and indirectly.
Adjuvant interventions: Over 60% of trials (74) offered—in addition to the study intervention—treatment as usual, such as individual counseling, cognitive behavioral counseling, or 12-step based approaches.
Efficacy: The majority of trials—46% or 60 studies—found no significant improvement in craving measures by time or group intervention. In approximately 21% of trials, or 27 studies, the active drug intervention suppressed craving and differentiated from placebo.
A total of 84 studies evaluated both craving and cocaine use as outcomes, 76% of them (64) presented a direct correlation between craving and cocaine use after the treatment. The other studies (20) showed divergent results.
First, we separated the studies into two large groups according to the duration of intervention: Acute interventions when up to 7 days and Sub-Acute interventions for more than 7 days. Within each large group, pharmacotherapies were divided into pharmacological classes: antidepressants, antipsychotics, psychostimulants, and other drugs. Detailed data is depicted in Table 1, Table 2, Table 3, Table 4 and Table 5.

3.6. Acute Interventions

3.6.1. Antidepressants

One study administering acute fenfluramine [22] found evidence of anti-craving effects 2-fold greater than placebo.

3.6.2. Psychostimulants

Acute administration of serotonergic (5HT) agonist meta-chlorophenylpiperazine (m-CCP) [39] led to a substantial reduction (20%) in craving. The 5HT agonist lorcaserin in a single dose showed mixed results; it had anti-craving effect only after placebo IV doses, but not after IV cocaine doses [58].

3.6.3. Other Drugs

The dopaminergic (DA) precursor depletion method (APTD) significantly reduced both cue- and cocaine-induced craving [112]. Two trials of noradrenergic (NA) agonists—one with clonidine [103] and one with guanfacine [99]—resulted in improvement in craving compared to placebo, while another study with guanfacine reported negative results [121]. Finally, the beta NA blocker propranolol, compared to placebo, significantly reduced craving in a single-dose study [134].

3.7. Sub-Acute Interventions

3.7.1. Antidepressants

No study among the six trials involving selective serotonin reuptake inhibitors (fluoxetine, paroxetine, fenfluramine) found evidence of anti-craving effects [21,25,27,28,33,36]). Among the trials involving dual action in 5HT and NA signaling (venlafaxine, citicoline, nefazodone, desipramine) [20,23,24,26,29,30,31,34], two found a statistically significant reduction in cocaine craving: one study administering long-term desipramine [26], and one study administering long-term nefazodone [24]. Mirtazapine 30 mg daily showed significant anti-craving effect in one study [32], while no effect in craving in another trial [19]. Lastly, bupropion [35] did not have demonstrable craving suppression effects.

3.7.2. Antipsychotics

Aripiprazole led to a significant reduction in craving in one study [66], while another two studies [70,71] did not differentiate from placebo. Studies administering olanzapine [65,67,68,72], quetiapine [76] and risperidone [65,69,74] did not find evidence of craving suppression effects either. When compared to haloperidol, olanzapine demonstrated significantly better results in one trial [75], while another showed that haloperidol [73] was significantly better in reducing craving than olanzapine.

3.7.3. Psychostimulants

Among studies administering modafinil, two [38,51] out of seven studies [38,42,43,44,46,51,52] found significant improvements in cocaine craving; as did another three studies administering amphetamine [48], lisdexamphetamine [55] and methamphetamine [54]. Two trials testing the use of lorcaserin 20 mg daily [49,60] showed significant decreases in craving compared to placebo. Studies with atomoxetine [40,64], dexamphetamine [56,62], diethylpropion [37], mazindol [57,63,127], methylphenidate [47,53,59,61], ritanserin [41,45,50] did not demonstrate anti-craving effects.

3.7.4. Anticonvulsants

Only one study [80] of two [23,80] comparing carbamazepine to placebo showed a significant decrease in craving. The anticonvulsant topiramate was found to have anti-craving effects in two [81,82] out of four trials [81,82,83,86]. The trials with baclofen [141], gabapentin [77], lamotrigine [78], phenytoin [79], tiagabine [87], valproate [72,84] and vigabatrin [144] reported no significant effect on cocaine craving in comparison with placebo.

3.7.5. Other Drugs

Nicotinergic agonists (nicotine and varenicline) were investigated in two trials, and an antagonist (mecamylamine) in two studies: mecamylamine significantly reduced craving in one trial [85], while in another [131] only the placebo group showed significant reduction; transdermal nicotine significantly increased cue-induced craving in comparison to placebo in one trial [145] while varenicline [126] did not differ from the placebo. Biperiden, a muscarinic antagonist, reduced craving by 37.6%, compared to a 19% change from baseline produced by the placebo [96]. Bromocriptine led to a significant reduction in craving in one study [92], while another two [97,102] did not differentiate from the placebo. The DA precursors levodopa/carbidopa, administered for more than 5 weeks and combined with non-pharmacological therapies, were found to reduce craving in one [138] of two studies [120,138], in which it was administered for a longer period (12 weeks) and combined with cognitive behavioral therapy. The administration of amantadine was found to have anti-craving effects in one [140] of three [101,109,140] studies; as citicoline did in one [132] out of three studies [90,113,132]. Two [100,117] studies in three [100,117,146] comparing 7 days of allopregnanolone to the placebo showed a significant decrease in craving. Ketamine showed a significant craving reduction in one [93] of the three studies [93,94,95]. The PPAR (Peroxisome proliferator-activated receptor)-Gamma agonist Pioglitazone reduced cocaine craving by a factor of b = 0.24 when compared to a factor of b = 0.09 for participants receiving placebo [136].
Oral naltrexone, an opioid receptor antagonist, did not show any difference in craving in comparison to the placebo [118,137]; as well as the glutamatergic partial agonist D-cycloserine [106,128,129,135]. Propranolol, compared to the placebo, did not reduce craving in long-term studies [104,108,134]. The Calcium Channel Antagonists amlodipine [115], isradipine [105] and nimodipine [133]; acamprosate [147]; the Cocaine esterase RBP- 8000 [123]; the Cox-2 inhibitor celecoxib [130]; disulfiram [125]; ecopipam [122]; L-tryptophan [91]; lidocaine [88]; memantine [89]; the corticosteroids metyrapone [107,110]; N-acetylcysteine [139,143,148]; pergolide [114]; pramipexole [124]; reserpine [142]; riluzole [25], selegiline [98] and cannabidiol [116,119] showed no differences compared to the placebo either. In a study, participants who received oxytocin experienced more severe cocaine craving relative to the placebo [111].

3.8. Treatment Dropout

Attrition varied widely among clinical trials, ranging from 0 to 82%, with an average attrition of 40%. Twenty-seven trials did not report their dropout rate. Among the studies with outpatients, 32% showed more than half of the sample dropped out at the end of intervention, against 14% of the inpatient trials. Half of the studies with 5HT agents had an attrition rate greater than 50%. Notably, studies that included adjuvant non-pharmacological therapies had lower attrition rates.

4. Discussion

We sought to systematically review and appraise the evidence base on pharmacological interventions for cocaine craving, an important treatment target for cocaine use disorder. Altogether, we appraised 130 clinical trials examining a wide range of compounds, with several mechanisms of action. From the analysis of the current review, we observed correlation between craving and cocaine use outcomes (self-reports, timeline follow-back or urinary BE) in the vast majority of studies. Therefore, we can consider craving as an intermediate target for achieving abstinence.
We highlighted here the promising drugs presented in the studies that scored equal to or greater than six points in the quality assessment. In the short-term treatment, acute phenylalanine-tyrosine depletion (1 study with significant positive anti-craving effects in 1 study included in the present review), clonidine (1/1), fenfluramine (1/1), and m-CPP (1/1), mecamylamine (1/2) presented promising effects. In the long term, lorcaserin (2/2) amphetamine (1/1), biperiden (1/1), carbamazepine (1/1), lisdexamfetamine (1/1), methamphetamine (1/1), pioglitazone (1/1), progesterone (2/3), guanfacine (1/2), levodopa (1/2), mirtazapine (1/2) and nefazodone (1/2) presented promising anti-craving effects. Unfortunately, the highly tested medications were not successful in most of the trials, as follows: propranolol (1/3) in the short term; amantadine (1/3), aripiprazole (1/3), bromocriptine (1/3), citicoline (1/3), ketamine (1/3), modafinil (2/7), olanzapine (1/4), topiramate (1/4) in the long term.
Craving can be triggered by the drug itself, by cues related to drug use, by stress, and by withdrawal. It may occur in the period of immediate abstinence or in a longer period of abstinence. In the first process, there is an immediate activation of limbic system related to an anticipatory state and reward expectancy, and a disruption of medial prefrontal activity leading to compulsive drug-related behavior [4]. Despite having a low number of studies, clonidine, fenfluramine and m-CPP showed to be promising medications for acute anti-craving effects, based on the experimental studies (i.e., cue-induced, stress-induced) included in this review.
The craving that occurs after a longer period of abstinence, on the other hand, can be better explained by the incubation mechanism, in which even after drug use suspension and exposure to drug cues, there is a progressive increase in craving, remaining high within 3 months of abstinence, with a reduction after 6 months and is related to neuroadaptations and increased brain-derived neurotrophic factor (BDNF) levels [149]. The most promising drugs for such chronic purposes came from the longer randomized controlled trials included in this review. The class of psychostimulants had several options such as amphetamine, lisdexamfetamine, lorcaserin and methamphetamine for chronic cocaine craving. Our findings are in line with a review [150] of 9 clinical trials, of which 4 evaluated craving and one showed a significant anti- craving effect of dexamphetamine. Progesterone was shown to be effective for treating craving in two out of three studies, in cocaine-dependent men and women who used the drug for 7 consecutive days. The antidepressant mirtazapine also showed a significant reduction in craving in 1 of 2 studies with it. Carbamazepine, biperiden and pioglitazone also presented significant anti-craving effects in long term treatments, although each one was evaluated once.
There are currently no approved drugs for the treatment of cocaine use disorder, with psychosocial intervention still being the standard approach. Recommendations of United Nations Office on Drugs and Crime [151] state that stimulant medications, such as amphetamines, may have modest effects on withdrawal and craving suppression for patients with stimulant use disorder. These recommendations refer to stimulants as “replacement” or “substitution therapy” and highlight studies that found evidence of craving suppression following the administration of extended-release formulations of methamphetamine 30 mg/day and lisdexamphetamine 70 mg/day. Findings of this review endorse these recommendations, but not the recommendations of The European Monitoring Centre for Drugs and Drugs Addiction, which stated in a summary of systematic reviews [152] that antipsychotics are the most prominent anti-craving drugs, although this could not be established as effective treatment. Several studies have been conducted to evaluate the efficacy of pharmacotherapies regarding dual substance disorders: some reports indicated that buprenorphine decreases cocaine use [153,154,155] in opioid-dependent humans who were concurrently abusing cocaine; one in particular [155] evaluated craving and demonstrated a significant reduction in its rate. Recent studies examined the therapeutic potential of orexin receptor antagonists in rodent models of cocaine use disorder, in reducing cocaine seeking behavior [156,157], pointing to future directions in studies in clinical settings.
We found that most studies made direct comparisons of one individual compound to placebo, or indirect comparisons between more than one individual compound and placebo. None of the studies investigated the anti-craving effects of combined pharmacological interventions. This is in stark contrast with the complex, multi-system pathophysiology of craving, which may require a combination of pharmacotherapies with complementary mechanisms [2,4,5]. This is exemplified by a randomized, placebo-controlled trial investigating the combination of topiramate and sustained release amphetamine among 127 persons with cocaine dependence, which found significant anti-craving effects over 12 weeks [158]. A pre-clinical study [159] suggested that the combination of buprenorphine and naltrexone decreases compulsive cocaine self-administration with minimal liability to produce opioid dependence and may be useful as a treatment for cocaine addiction. Hence, multi-function therapies maybe represent a more promising avenue of intervention.
Moreover, as craving is elicited by cues, stress, drug and withdrawal, studies must include, besides laboratory assessment, Ecological Momentary Assessment (EMA) due to the temporal association between exposure to drug cues, or subjective experiences, allowing for a more dynamic investigation of therapeutic effects of anti-craving treatments.

Limitations

To our knowledge, this is the first systematic review of pharmacotherapies targeting cocaine craving. Our review has notable strengths. First, published and widely accepted guidelines to conduct and report systematic reviews were used [17]. A highly sensitive search strategy was used across several electronic databases, which yielded multiple studies providing data on anti-craving efficacy of pharmacotherapies. Further, 2 independent reviewers performed all stages of the review, with good interrater reliability.
Previous reviews [11,12,13,14] reported challenges in systematically assessing anti-craving effects across multiple studies, primarily due to a high heterogeneity of craving measures. For instance, some studies used standardized scales whereas other studies used Visual Analogue Scales (VAS), or non-standardized questionnaires, some with unclear psychometrical properties. A study [16] comparing unidimensional and multidimensional craving scales suggested that the latter had higher predictive validity for relapse of cocaine use and for treatment dropout. Further, a review of craving measures [7] even suggests that researchers use different scales within the same study due to its complexity. Still, our review was limited by high heterogeneity of craving assessments across studies and by a great range of pharmacotherapies. Further, the majority of the studies considered abstinence retention as the main outcome in cocaine treatment, whereas craving was a secondary outcome; also, some of the studies evaluated patients with cocaine use disorder with comorbidities such as opioid or alcohol use disorder, schizophrenia, bipolar disorder or attention deficit hyperactivity Lastly, most of the studies also included non-pharmacological treatments, such as counseling or psychotherapy. Nonetheless, the results of the review help bring clarity to the mixed findings on anti-craving pharmacotherapies reported in multiple clinical trials.

5. Conclusions

There is a direct association between craving and cocaine use, underscoring craving as an important treatment target for promoting abstinence among persons with cocaine use disorder. Given its clinical relevance, future studies aiming to develop pharmacotherapies for cocaine use disorder must consider craving as a therapeutic outcome, employing multimodal and standardized assessments—neurophysiological biomarkers, cue reactivity, ecological momentary assessment—to study this complex experience.
Despite most of the studies evaluate craving as a secondary outcome and having a low number of studies per medication in most of the cases, clonidine, fenfluramine and m-CPP showed to be promising medications for cocaine craving in the short-term treatment. In addition, amphetamine, biperiden, carbamazepine, levodopa, lisdexamfetamine, lorcaserin, guanfacine, methamphetamine, mirtazapine, pioglitazone, progesterone, nefazodone exhibited anti-craving effects in long-term treatment. Future trials targeting craving as the main outcome should include these medications trying to replicate their preliminary positive results.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/brainsci12111546/s1, Table S1: Structured cocaine craving scales.; Table S2: Results of the quality/bias assessment using the Cochrane Collaboration tool for assessing risk of bias.

Author Contributions

Conceptualization, D.L.S.L. and J.M.C.-M.; methodology J.M.C.-M.; formal analysis, J.P.D.A.; writing—original draft preparation, D.L.S.L.; writing—review and editing, J.P.D.A., A.M., A.B.N.; visualization, L.F.; supervision, J.M.C.-M. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Data Availability Statement

All the supporting data are presented in the manuscript.

Acknowledgments

There are no relevant financial or non-financial competing interests to report.

Conflicts of Interest

The authors declare no conflict of interest.

Systematic Review Registration

https://osf.io/f3hym/ (accessed on 10 November 2022).

References

  1. United Nations Office on Drugs and Crime. Treatment of Stimulant Use Disorders: Current Practices and Promising Per-spectives. 2017. Available online: https://www.unodc.org/documents/drug-prevention-and-treatment/Treatment_of_PSUD_for_website_24.05.19.pdf (accessed on 10 November 2022).
  2. Sinha, R. New Findings on Biological Factors Predicting Addiction Relapse Vulnerability. Curr. Psychiatry Rep. 2011, 13, 398–405. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  3. American Psychiatric Association. Substance Use Disorders. In Diagnostic and statistical manual of mental disorders (5th ed.). Indian J. Psychiatry 2013, 55, 220–223. [Google Scholar] [CrossRef] [PubMed]
  4. Sinha, R. The clinical neurobiology of drug craving. Curr. Opin. Neurobiol. 2013, 23, 649–654. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  5. Robinson, T.E.; Berridge, K.C. The neural basis of drug craving: An incentive-sensitization theory of addiction. Brain Res. Rev. 1993, 18, 247–291. [Google Scholar] [CrossRef]
  6. Childress, A.R.; Mozley, P.D.; McElgin, W.; Fitzgerald, J.; Reivich, M.; O’Brien, C.P. Limbic Activation During Cue-Induced Cocaine Craving. Am. J. Psychiatry 1999, 156, 11–18. [Google Scholar] [CrossRef] [Green Version]
  7. Mezinskis, J.P.; Honos-Webb, L.; Kropp, F.; Somoza, E. The Measurement of Craving. J. Addict. Dis. 2001, 20, 67–85. [Google Scholar] [CrossRef]
  8. Grant, S.; London, E.D.; Newlin, D.B.; Villemagne, V.L.; Liu, X.; Contoreggi, C.; Phillips, R.L.; Kimes, A.S.; Margolin, A. Activation of memory circuits during cue-elicited cocaine craving. Proc. Natl. Acad. Sci. USA 1996, 93, 12040–12045. [Google Scholar] [CrossRef] [Green Version]
  9. Kilts, C.D.; Schweitzer, J.B.; Quinn, C.K.; Gross, R.E.; Faber, T.L.; Muhammad, F.; Ely, T.D.; Hoffman, J.M.; Drexler, K.P.G. Neural Activity Related to Drug Craving in Cocaine Addiction. Arch. Gen. Psychiatry 2001, 58, 334–341. [Google Scholar] [CrossRef] [Green Version]
  10. Volkow, N.D.; Fowler, J.S.; Wolf, A.P.; Hitzemann, R.; Dewey, S.; Bendriem, B.; Alpert, R.; Hoff, A. Changes in brain glucose metabolism in cocaine dependence and withdrawal. Am. J. Psychiatry 1991, 148, 621–626. [Google Scholar] [CrossRef]
  11. Castells, X.; Casas, M.; Vidal, X.; Bosch, R.; Roncero, C.; Ramos-Quiroga, J.A.; Capellà, D. Efficacy of central nervous system stimulant treatment for cocaine dependence: A systematic review and meta-analysis of randomized controlled clinical trials. Addiction 2007, 102, 1871–1887. [Google Scholar] [CrossRef]
  12. Indave, B.I.; Minozzi, S.; Pani, P.P.; Amato, L. Antipsychotic medications for cocaine dependence. Cochrane Database Syst. Rev. 2016, 2016, CD006306. [Google Scholar] [CrossRef] [PubMed]
  13. Minozzi, S.; Cinquini, M.; Amato, L.; Davoli, M.; Farrell, M.F.; Pani, P.P.; Vecchi, S. Anticonvulsants for cocaine dependence. Cochrane Database Syst. Rev. 2015, 4, CD006754. [Google Scholar] [CrossRef]
  14. Pani, P.P.; Trogu, E.; Vecchi, S.; Amato, L. Antidepressants for cocaine dependence and problematic cocaine use. Cochrane Database Syst. Rev. 2011, 12, CD002950. [Google Scholar] [CrossRef] [PubMed]
  15. Eliason, M.J.; Amodia, D.S. An integral approach to drug craving. Addict. Res. Theory 2007, 15, 343–364. [Google Scholar] [CrossRef]
  16. Heinz, A.J.; Epstein, D.H.; Schroeder, J.R.; Singleton, E.G.; Heishman, S.J.; Preston, K.L. Heroin and cocaine craving and use during treatment: Measurement validation and potential relationships. J. Subst. Abus. Treat. 2006, 31, 355–364. [Google Scholar] [CrossRef]
  17. Page, M.J.; McKenzie, J.E.; Bossuyt, P.M.; Boutron, I.; Hoffmann, T.C.; Mulrow, C.D.; Shamseer, L.; Tetzlaff, J.M.; Akl, E.A.; Brennan, S.E.; et al. The PRISMA 2020 Statement: An Updated Guideline for Reporting Systematic Reviews. BMJ 2021, 372, n71. [Google Scholar] [CrossRef]
  18. Higgins, J.P.T.; Altman, D.G.; Gøtzsche, P.C.; Jüni, P.; Moher, D.; Oxman, A.D.; Savović, J.; Schulz, K.F.; Weeks, L.; Sterne, J.A.C.; et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 2011, 343, d5928. [Google Scholar] [CrossRef] [Green Version]
  19. Afshar, M.; Knapp, C.; Sarid-Segal, O.; Devine, E.; Colaneri, L.S.; Tozier, L.; Waters, M.E.; Putnam, M.A.; Ciraulo, D. The Efficacy of Mirtazapine in the Treatment of Cocaine Dependence with Comorbid Depression. Am. J. Drug Alcohol Abus. 2012, 38, 181–186. [Google Scholar] [CrossRef] [Green Version]
  20. Arndt, I.O.; Dorozynsky, L.; Woody, G.E.; McLellan, A.T.; O’Brien, C.P. Desipramine Treatment of Cocaine Dependence in Methadone-Maintained Patients. Arch. Gen. Psychiatry 1992, 49, 888–893. [Google Scholar] [CrossRef]
  21. Batki, S.L.; Washburn, A.M.; Delucchi, K.; Jones, R.T. A controlled trial of fluoxetine in crack cocaine dependence. Drug Alcohol Depend. 1996, 41, 137–142. [Google Scholar] [CrossRef]
  22. Buydens-Branchey, L.; Branchey, M.; Hudson, J.; Rothman, M.; Fergeson, P.; McKernin, C. Effect of fenfluramine chal-lenge on cocaine craving in addicted male users. Am. J. Addict. 1998, 7, 142–155. [Google Scholar] [CrossRef] [PubMed]
  23. Campbell, J.; Nickel, E.J.; Penick, E.C.; Wallace, D.; Gabrielli, W.F.; Rowe, C.; Liskow, B.; Powell, B.J.; Thomas, H.M. Comparison of desipramine or carbamazepine to placebo for crack cocaine-dependent patients. Am. J. Addict. 2003, 12, 122–136. [Google Scholar] [CrossRef] [PubMed]
  24. Ciraulo, D.A.; Knapp, C.; Rotrosen, J.; Sarid-Segal, O.; Ciraulo, A.M.; LoCastro, J.; Greenblatt, D.J.; Leiderman, D. Nefazodone treatment of cocaine dependence with comorbid depressive symptoms. Addiction 2005, 100, 23–31. [Google Scholar] [CrossRef]
  25. Ciraulo, D.A.; Sarid-Segal, O.; Knapp, C.M.; Ciraulo, A.M.; LoCastro, J.; Bloch, D.A.; Montgomery, M.A.; Leiderman, D.B.; Elkashef, A. Efficacy screening trials of paroxetine, pentoxifylline, riluzole, pramipexole and venlafaxine in cocaine dependence. Addiction 2005, 100, 12–22. [Google Scholar] [CrossRef] [PubMed]
  26. Gawin, F.H.; Kleber, H.D.; Byck, R.; Rounsaville, B.J.; Kosten, T.R.; Jatlow, P.I.; Morgan, C. Desipramine Facilitation of Initial Cocaine Abstinence. Arch. Gen. Psychiatry 1989, 46, 117–121. [Google Scholar] [CrossRef]
  27. Grabowski, J.; Rhoades, H.; Elk, R.; Schmitz, J.; Davis, C.; Creson, D.; Kirby, K. Fluoxetine Is Ineffective for Treatment of Cocaine Dependence or Concurrent Opiate and Cocaine Dependence: Two placebo-controlled double-blind trials. J. Clin. Psychopharmacol. 1995, 15, 163–174. [Google Scholar] [CrossRef]
  28. Harris, D.S.; Batki, S.L.; Berger, S.P. Fluoxetine Attenuates Adrenocortical but Not Subjective Responses to Cocaine Cues. Am. J. Drug Alcohol Abus. 2004, 30, 765–782. [Google Scholar] [CrossRef] [PubMed]
  29. Kolar, A.F.; Brown, B.S.; Weddington, W.W.; Haertzen, C.C.; Michaelson, B.S.; Jaffe, J.H. Treatment of Cocaine Dependence in Methadone Maintenance Clients: A Pilot Study Comparing the Efficacy of Desipramine and Amantadine. Int. J. Addict. 1992, 27, 849–868. [Google Scholar] [CrossRef]
  30. Kosten, T.R.; Morgan, C.M.; Falcione, J.; Schottenfeld, R.S. Pharmacotherapy for Cocaine-Abusing Methadone-Maintained Patients Using Amantadine or Desipramine. Arch. Gen. Psychiatry 1992, 49, 894–898. [Google Scholar] [CrossRef]
  31. McDowell, D.; Nunes, E.V.; Seracini, A.M.; Rothenberg, J.; Vosburg, S.K.; Ma, G.J.; Petkova, E. Desipramine treatment of cocaine-dependent patients with depression: A placebo-controlled trial. Drug Alcohol Depend. 2005, 80, 209–221. [Google Scholar] [CrossRef]
  32. Nanni-Alvarado, R.; Gonzalez, M.; Lima, C.; Marín-Navarrete, R.; Barbosa-Méndez, S.; Salazar-Juárez, A. Effect of Mirtazapine on Craving in Cocaine-Dependent Patients. Int. J. Ment. Health Addict. 2021, 20, 2770–2786. [Google Scholar] [CrossRef]
  33. Oliveto, A.; Kosten, T.R.; Schottenfeld, R.; Falcioni, J.; Ziedonis, D. Desipramine, amantadine, or fluoxetine in buprenorphine-maintained cocaine users. J. Subst. Abus. Treat. 1995, 12, 423–428. [Google Scholar] [CrossRef]
  34. Passos, S.R.L.; Camacho, L.A.B.; Lopes, C.D.S.; Dos Santos, M.A.B. Nefazodone in out-patient treatment of inhaled cocaine dependence: A randomized double-blind placebo-controlled trial. Addiction 2005, 100, 489–494. [Google Scholar] [CrossRef] [PubMed]
  35. Shoptaw, S.; Heinzerling, K.G.; Rotheram-Fuller, E.; Kao, U.H.; Wang, P.-C.; Bholat, M.A.; Ling, W. Bupropion Hydrochloride versus Placebo, in Combination with Cognitive Behavioral Therapy, for the Treatment of Cocaine Abuse/Dependence. J. Addict. Dis. 2008, 27, 13–23. [Google Scholar] [CrossRef] [PubMed]
  36. Winstanley, E.L.; Bigelow, G.E.; Silverman, K.; Johnson, R.E.; Strain, E.C. A randomized controlled trial of fluoxetine in the treatment of cocaine dependence among methadone-maintained patients. J. Subst. Abus. Treat. 2011, 40, 255–264. [Google Scholar] [CrossRef] [Green Version]
  37. Alim, T.N.; Rosse, R.B.; Vocci, F.J.; Lindquist, T.; Deutsch, S.I. Diethylpropion Pharmacotherapeutic Adjuvant Therapy for Inpatient Treatment of Cocaine Dependence: A test of the cocaine-agonist hypothesis. Clin. Neuropharmacol. 1995, 18, 183–195. [Google Scholar] [CrossRef]
  38. Anderson, A.L.; Reid, M.S.; Li, S.-H.; Holmes, T.; Shemanski, L.; Slee, A.; Smith, E.V.; Kahn, R.; Chiang, N.; Vocci, F.; et al. Modafinil for the treatment of cocaine dependence. Drug Alcohol Depend. 2009, 104, 133–139. [Google Scholar] [CrossRef] [Green Version]
  39. Buydens-Branchey, L.; Branchey, M.; Fergeson, P.; Hudson, J.; McKernin, C. Craving for cocaine in addicted users. Role of serotonergic mechanisms. Am. J. Addict. 1997, 6, 65–73. [Google Scholar]
  40. Cantilena, L.; Kahn, R.; Duncan, C.C.; Li, S.-H.; Anderson, A.; Elkashef, A. Safety of Atomoxetine in Combination With Intravenous Cocaine in Cocaine-Experienced Participants. J. Addict. Med. 2012, 6, 265–273. [Google Scholar] [CrossRef] [Green Version]
  41. Cornish, J.W.; Maany, I.; Fudala, P.J.; Ehrman, R.N.; Robbins, S.J.; O’Brien, C.P. A randomized, double-blind, placebo-controlled study of ritanserin pharmacotherapy for cocaine dependence. Drug Alcohol Depend. 2000, 61, 183–189. [Google Scholar] [CrossRef]
  42. Dackis, C.A.; Lynch, K.G.; Yu, E.; Samaha, F.F.; Kampman, K.M.; Cornish, J.W.; Rowan, A.; Poole, S.; White, L.; O’Brien, C.P. Modafinil and cocaine: A double-blind, placebo-controlled drug interaction study. Drug Alcohol Depend. 2002, 70, 29–37. [Google Scholar] [CrossRef]
  43. Dackis, C.A.; Kampman, K.M.; Lynch, K.G.; Pettinati, H.M.; O’Brien, C.P. A Double-Blind, Placebo-Controlled Trial of Modafinil for Cocaine Dependence. Neuropsychopharmacology 2004, 30, 205–211. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  44. Dackis, C.A.; Kampman, K.M.; Lynch, K.G.; Plebani, J.G.; Pettinati, H.M.; Sparkman, T.; O’Brien, C.P. A double-blind, placebo-controlled trial of modafinil for cocaine dependence. J. Subst. Abus. Treat. 2012, 43, 303–312. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  45. Ehrman, R.N.; Robbins, S.J.; Cornish, J.W.; Childress, A.R.; O’Brien, C.P. Failure of ritanserin to block cocaine cue reactivity in humans. Drug Alcohol Depend. 1996, 42, 167–174. [Google Scholar] [CrossRef]
  46. Goudriaan, A.E.; Veltman, D.J.; Brink, W.V.D.; Dom, G.; Schmaal, L. Neurophysiological effects of modafinil on cue-exposure in cocaine dependence: A randomized placebo-controlled cross-over study using pharmacological fMRI. Addict. Behav. 2013, 38, 1509–1517. [Google Scholar] [CrossRef]
  47. Grabowski, J.; Roache, J.D.; Schmitz, J.; Rhoades, H.; Creson, D.; Korszun, A. Replacement Medication for Cocaine Dependence: Methylphenidate. J. Clin. Psychopharmacol. 1997, 17, 485–488. [Google Scholar] [CrossRef]
  48. Greenwald, M.K.; Lundahl, L.H.; Steinmiller, C.L. Sustained Release d-Amphetamine Reduces Cocaine but not ‘Speedball’-Seeking in Buprenorphine-Maintained Volunteers: A Test of Dual-Agonist Pharmacotherapy for Cocaine/Heroin Polydrug Abusers. Neuropsychopharmacology 2010, 35, 2624–2637. [Google Scholar] [CrossRef] [Green Version]
  49. Johns, S.E.; Keyser-Marcus, L.; Abbate, A.; Boone, E.; Van Tassell, B.; Cunningham, K.A.; Anastasio, N.C.; Poklis, J.L.; Ramey, T.; Moeller, F.G. Safety and Preliminary Efficacy of Lorcaserin for Cocaine Use Disorder: A Phase I Randomized Clinical Trial. Front. Psychiatry 2021, 12, 666945. [Google Scholar] [CrossRef]
  50. Johnson, B.A.; Chen, Y.R.; Swann, A.C.; Schmitz, J.; Lesser, J.; Ruiz, P.; Johnson, P.; Clyde, C. Ritanserin in the treatment of cocaine dependence. Biol. Psychiatry 1997, 42, 932–940. [Google Scholar] [CrossRef]
  51. Kampman, K.M.; Lynch, K.G.; Pettinati, H.M.; Spratt, K.; Wierzbicki, M.R.; Dackis, C.; O’Brien, C.P. A double blind, placebo controlled trial of modafinil for the treatment of cocaine dependence without co-morbid alcohol dependence. Drug Alcohol Depend. 2015, 155, 105–110. [Google Scholar] [CrossRef] [Green Version]
  52. Karila, L.; Leroy, C.; Dubol, M.; Trichard, C.; Mabondo, A.; Marill, C.; Dubois, A.; Bordas, N.; Martinot, J.-L.; Reynaud, M.; et al. Dopamine Transporter Correlates and Occupancy by Modafinil in Cocaine-Dependent Patients: A Controlled Study With High-Resolution PET and [11C]-PE2I. Neuropsychopharmacology 2016, 41, 2294–2302. [Google Scholar] [CrossRef] [PubMed]
  53. Levin, F.R.; Evans, S.M.; Brooks, D.J.; Garawi, F. Treatment of cocaine dependent treatment seekers with adult ADHD: Double-blind comparison of methylphenidate and placebo. Drug Alcohol Depend. 2007, 87, 20–29. [Google Scholar] [CrossRef] [PubMed]
  54. Mooney, M.E.; Herin, D.V.; Schmitz, J.; Moukaddam, N.; Green, C.E.; Grabowski, J. Effects of oral methamphetamine on cocaine use: A randomized, double-blind, placebo-controlled trial. Drug Alcohol Depend. 2009, 101, 34–41. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  55. Mooney, M.E.; Herin, D.V.; Specker, S.; Babb, D.; Levin, F.R.; Grabowski, J. Pilot study of the effects of lisdexamfetamine on cocaine use: A randomized, double-blind, placebo-controlled trial. Drug Alcohol Depend. 2015, 153, 94–103. [Google Scholar] [CrossRef] [Green Version]
  56. Nuijten, M.; Blanken, P.; van de Wetering, B.; Nuijen, B.; Brink, W.V.D.; Hendriks, V.M. Sustained-release dexamfetamine in the treatment of chronic cocaine-dependent patients on heroin-assisted treatment: A randomised, double-blind, placebo-controlled trial. Lancet 2016, 387, 2226–2234. [Google Scholar] [CrossRef]
  57. Perry, E.B.; Gil, R.; Miles, D.; Brenner, L.; MacDougall, L.; Johnson, R.; Degen, K.; Gueorguieva, R.; Petrakis, I.L.; Krystal, J.H.; et al. Mazindol Augmentation of Antipsychotic Treatment for Schizophrenic Patients with Comorbid Cocaine Abuse or Dependence. J. Dual Diagn. 2005, 1, 37–47. [Google Scholar] [CrossRef]
  58. Pirtle, J.L.; Hickman, M.D.; Boinpelly, V.C.; Surineni, K.; Thakur, H.K.; Grasing, K.W. The serotonin-2C agonist Lorcaserin delays intravenous choice and modifies the subjective and cardiovascular effects of cocaine: A randomized, controlled human laboratory study. Pharmacol. Biochem. Behav. 2019, 180, 52–59. [Google Scholar] [CrossRef]
  59. Roache, J.D.; Grabowski, J.; Schmitz, J.M.; Creson, D.L.; Rhoades, H.M. Laboratory Measures of Methylphenidate Effects in Cocaine-Dependent Patients Receiving Treatment. J. Clin. Psychopharmacol. 2000, 20, 61–68. [Google Scholar] [CrossRef]
  60. Santos, G.-M.; Ikeda, J.; Coffin, P.; Walker, J.E.; Matheson, T.; McLaughlin, M.; Jain, J.; Vittinghoff, E.; Batki, S.L. Pilot study of extended-release lorcaserin for cocaine use disorder among men who have sex with men: A double-blind, placebo-controlled randomized trial. PLoS ONE 2021, 16, e0254724. [Google Scholar] [CrossRef]
  61. Schubiner, H.; Downey, K.K.; Arfken, C.L.; Johanson, C.-E.; Schuster, C.R.; Lockhart, N.; Edwards, A.; Donlin, J.; Pihlgren, E. Double-blind placebo-controlled trial of methylphenidate in the treatment of adult ADHD patients with comorbid cocaine dependence. Exp. Clin. Psychopharmacol. 2002, 10, 286–294. [Google Scholar] [CrossRef]
  62. Shearer, J.; Wodak, A.; Van Beek, I.; Mattick, R.P.; Lewis, J. Pilot randomized double blind placebo-controlled study of dexamphetamine for cocaine dependence. Addiction 2003, 98, 1137–1141. [Google Scholar] [CrossRef] [PubMed]
  63. Stine, S.M.; Krystal, J.H.; Kosten, T.R.; Charney, D.S. Mazindol treatment for cocaine dependence. Drug Alcohol Depend. 1995, 39, 245–252. [Google Scholar] [CrossRef]
  64. Walsh, S.L.; Middleton, L.S.; Wong, C.J.; Nuzzo, P.A.; Campbell, C.L.; Rush, C.R.; Lofwall, M.R. Atomoxetine does not alter cocaine use in cocaine dependent individuals: A double blind randomized trial. Drug Alcohol Depend. 2012, 130, 150–157. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  65. Akerele, E.; Levin, F.R. Comparison of Olanzapine to Risperidone in Substance-Abusing Individuals with Schizophrenia. Am. J. Addict. 2007, 16, 260–268. [Google Scholar] [CrossRef]
  66. Beresford, T.; Buchanan, J.; Thumm, E.B.; Emrick, C.; Weitzenkamp, D.; Ronan, P.J. Late Reduction of Cocaine Cravings in a Randomized, Double-Blind Trial of Aripiprazole vs Perphenazine in Schizophrenia and Comorbid Cocaine Dependence. J. Clin. Psychopharmacol. 2017, 37, 657–663. [Google Scholar] [CrossRef]
  67. Hamilton, J.D.; Nguyen, Q.X.; Gerber, R.M.; Rubio, N.B. Olanzapine in Cocaine Dependence: A Double-Blind, Placebo-Controlled Trial. Am. J. Addict. 2009, 18, 48–52. [Google Scholar] [CrossRef]
  68. Kampman, K.M.; Pettinati, H.; Lynch, K.G.; Sparkman, T.; O’Brien, C.P. A pilot trial of olanzapine for the treatment of cocaine dependence. Drug Alcohol Depend. 2003, 70, 265–273. [Google Scholar] [CrossRef]
  69. Loebl, T.; Angarita, G.A.; Pachas, G.N.; Huang, K.-L.; Lee, S.H.; Nino, J.; Logvineko, T.; Culhane, M.A.; Evins, A.E. A Randomized, Double-Blind, Placebo-Controlled Trial of Long-Acting Risperidone in Cocaine-Dependent Men. J. Clin. Psychiatry 2008, 69, 480–486. [Google Scholar] [CrossRef]
  70. Lofwall, M.R.; Nuzzo, P.A.; Campbell, C.; Walsh, S.L. Aripiprazole effects on self-administration and pharmacodynamics of intravenous cocaine and cigarette smoking in humans. Exp. Clin. Psychopharmacol. 2014, 22, 238–247. [Google Scholar] [CrossRef] [Green Version]
  71. Moran, L.M.; Phillips, K.A.; Kowalczyk, W.; Ghitza, U.E.; Agage, D.A.; Epstein, D.H.; Preston, K.L. Aripiprazole for cocaine abstinence: A randomized–controlled trial with ecological momentary assessment. Behav. Pharmacol. 2017, 28, 63–73. [Google Scholar] [CrossRef] [Green Version]
  72. Reid, M.S.; Casadonte, P.; Baker, S.; Sanfilipo, M.; Braunstein, D.; Hitzemann, R.; Montgomery, A.; Majewska, D.; Robinson, J.; Rotrosen, J. A placebo-controlled screening trial of olanzapine, valproate, and coenzyme Q10/L-carnitine for the treatment of cocaine dependence. Addiction 2005, 100, 43–57. [Google Scholar] [CrossRef] [PubMed]
  73. Sayers, S.L.; Campbell, E.C.; Kondrich, J.; Mann, S.C.; Cornish, J.; O’Brien, C.; Caroff, S.N. Cocaine Abuse in Schizophrenic Patients Treated With Olanzapine Versus Haloperidol. J. Nerv. Ment. Dis. 2005, 193, 379–386. [Google Scholar] [CrossRef] [PubMed]
  74. Smelson, D.A.; Williams, J.; Ziedonis, D.; Sussner, B.D.; Losonczy, M.F.; Engelhart, C.; Kaune, M. A double-blind placebo-controlled pilot study of risperidone for decreasing cue-elicited craving in recently withdrawn cocaine dependent patients. J. Subst. Abus. Treat. 2004, 27, 45–49. [Google Scholar] [CrossRef] [PubMed]
  75. Smelson, D.A.; Ziedonis, D.; Williams, J.; Losonczy, M.F.; Williams, J.; Steinberg, M.L.; Kaune, M. The Efficacy of Olanzapine for Decreasing Cue-Elicited Craving in Individuals With Schizophrenia and Cocaine Dependence: A preliminary report. J. Clin. Psychopharmacol. 2006, 26, 9–12. [Google Scholar] [CrossRef] [PubMed]
  76. Tapp, A.; Wood, A.E.; Kennedy, A.; Sylvers, P.; Kilzieh, N.; Saxon, A.J. Quetiapine for the treatment of cocaine use disorder. Drug Alcohol Depend. 2015, 149, 18–24. [Google Scholar] [CrossRef]
  77. Bisaga, A.; Aharonovich, E.; Garawi, F.; Levin, F.R.; Rubin, E.; Raby, W.N.; Nunes, E. A randomized placebo-controlled trial of gabapentin for cocaine dependence. Drug Alcohol Depend. 2006, 81, 267–274. [Google Scholar] [CrossRef]
  78. Brown, E.S.; Sunderajan, P.; Hu, L.T.; Sowell, S.M.; Carmody, T.J. A Randomized, Double-Blind, Placebo-Controlled, Trial of Lamotrigine Therapy in Bipolar Disorder, Depressed or Mixed Phase and Cocaine Dependence. Neuropsychopharmacology 2012, 37, 2347–2354. [Google Scholar] [CrossRef] [Green Version]
  79. Crosby, R.; Pearson, V.L.; Eller, C.; Winegarden, T.; Graves, N.L. Phenytoin in the treatment of cocaine abuse: A double-blind study*. Clin. Pharmacol. Ther. 1996, 59, 458–468. [Google Scholar] [CrossRef]
  80. Halikas, J.A.; Crosby, R.D.; Pearson, V.L.; Graves, N.M. A randomized double-blind study of carbamazepine in the treatment of cocaine abuse*. Clin. Pharmacol. Ther. 1997, 62, 89–105. [Google Scholar] [CrossRef]
  81. Johnson, B.A.; Roache, J.D.; Ait-Daoud, N.; Gunderson, E.W.; Haughey, H.M.; Wang, X.-Q.; Liu, L. Topiramate’s effects on cocaine-induced subjective mood, craving and preference for money over drug taking. Addict. Biol. 2012, 18, 405–416. [Google Scholar] [CrossRef] [Green Version]
  82. Johnson, B.A.; Ait-Daoud, N.; Wang, X.-Q.; Penberthy, J.K.; Javors, M.A.; Seneviratne, C.; Liu, L. Topiramate for the Treatment of Cocaine Addiction: A randomized clinical trial. JAMA Psychiatry 2013, 70, 1338–1346. [Google Scholar] [CrossRef] [PubMed]
  83. Kampman, K.M.; Pettinati, H.M.; Lynch, K.G.; Spratt, K.; Wierzbicki, M.R.; O’Brien, C.P. A double-blind, placebo-controlled trial of topiramate for the treatment of comorbid cocaine and alcohol dependence. Drug Alcohol Depend. 2013, 133, 94–99. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  84. Reid, M.S.; Thakkar, V. Valproate treatment and cocaine cue reactivity in cocaine dependent individuals. Drug Alcohol Depend. 2009, 102, 144–150. [Google Scholar] [CrossRef] [Green Version]
  85. Reid, M.S.; Mickalian, J.D.; Delucchi, K.L.; Berger, S.P. A nicotine antagonist, mecamylamine, reduces cue-induced cocaine craving in cocaine-dependent subjects. Neuropsychopharmacology 1999, 20, 297–307. [Google Scholar] [CrossRef] [Green Version]
  86. Umbricht, A.; DeFulio, A.; Winstanley, E.L.; Tompkins, D.A.; Peirce, J.; Mintzer, M.Z.; Strain, E.C.; Bigelow, G.E. Topiramate for cocaine dependence during methadone maintenance treatment: A randomized controlled trial. Drug Alcohol Depend. 2014, 140, 92–100. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  87. Winhusen, T.; Somoza, E.; Ciraulo, D.A.; Harrer, J.M.; Goldsmith, R.J.; Grabowski, J.; Coleman, F.S.; Mindrum, G.; Kahn, R.; Osman, S.; et al. A double-blind, placebo-controlled trial of tiagabine for the treatment of cocaine dependence. Drug Alcohol Depend. 2007, 91, 141–148. [Google Scholar] [CrossRef]
  88. Becker, J.; Price, J.L.; Leonard, D.; Suris, A.; Kandil, E.; Shaw, M.; Kroener, S.; Brown, E.S.; Adinoff, B. The Efficacy of Lidocaine in Disrupting Cocaine Cue-Induced Memory Reconsolidation. Drug Alcohol Depend. 2020, 212, 108062. [Google Scholar] [CrossRef]
  89. Bisaga, A.; Aharonovich, E.; Cheng, W.Y.; Levin, F.R.; Mariani, J.J.; Raby, W.N.; Nunes, E. A placebo-controlled trial of memantine for cocaine dependence with high-value voucher incentives during a pre-randomization lead-in period. Drug Alcohol Depend. 2010, 111, 97–104. [Google Scholar] [CrossRef] [Green Version]
  90. Brown, E.S.; Todd, J.P.; Hu, L.T.; Schmitz, J.M.; Carmody, T.J.; Nakamura, A.; Sunderajan, P.; Rush, A.J.; Adinoff, B.; Bret, M.E.; et al. A Randomized, Double-Blind, Placebo-Controlled Trial of Citicoline for Cocaine Dependence in Bipolar I Disorder. Am. J. Psychiatry 2015, 172, 1014–1021. [Google Scholar] [CrossRef]
  91. Chadwick, M.J.; Gregory, D.L.; Wendling, G. A Double-Blind Amino Acids, L-Tryptophan and L-Tyrosine, and Placebo Study with Cocaine-Dependent Subjects in an Inpatient Chemical Dependency Treatment Center. Am. J. Drug Alcohol Abus. 1990, 16, 275–286. [Google Scholar] [CrossRef]
  92. Dackis, C.A.; Gold, M.S.; Sweeney, D.R.; Byron, J.P.; Climko, R. Single-dose bromocriptine reverses cocaine craving. Psychiatry Res. 1987, 20, 261–264. [Google Scholar] [CrossRef]
  93. Dakwar, E.; Levin, F.; Foltin, R.W.; Nunes, E.V.; Hart, C.L. The Effects of Subanesthetic Ketamine Infusions on Motivation to Quit and Cue-Induced Craving in Cocaine-Dependent Research Volunteers. Biol. Psychiatry 2014, 76, 40–46. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  94. Dakwar, E.; Anerella, C.; Hart, C.; Levin, F.; Mathew, S.; Nunes, E. Therapeutic infusions of ketamine: Do the psychoactive effects matter? Drug Alcohol Depend. 2014, 136, 153–157. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  95. Dakwar, E.; Hart, C.L.; Levin, F.R.; Nunes, E.V.; Foltin, R.W. Cocaine self-administration disrupted by the N-methyl-D-aspartate receptor antagonist ketamine: A randomized, crossover trial. Mol. Psychiatry 2016, 22, 76–81. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  96. Dieckmann, L.H.J.; Ramos, A.C.; Silva, E.A.; Justo, L.P.; Sabioni, P.; Frade, I.F.; de Souza, A.L.; Galduróz, J.C.F. Effects of biperiden on the treatment of cocaine/crack addiction: A randomised, double-blind, placebo-controlled trial. Eur. Neuropsychopharmacol. 2014, 24, 1196–1202. [Google Scholar] [CrossRef]
  97. Eiler, K.; Schaefer, M.R.; Salstrom, D.; Lowery, R. Double-Blind Comparison of Bromocriptine and Placebo in Cocaine Withdrawal. Am. J. Drug Alcohol Abus. 1995, 21, 65–79. [Google Scholar] [CrossRef]
  98. Elkashef, A.; Fudala, P.J.; Gorgon, L.; Li, S.-H.; Kahn, R.; Chiang, N.; Vocci, F.; Collins, J.; Jones, K.; Boardman, K.; et al. Double-blind, placebo-controlled trial of selegiline transdermal system (STS) for the treatment of cocaine dependence. Drug Alcohol Depend. 2006, 85, 191–197. [Google Scholar] [CrossRef]
  99. Fox, H.C.; Seo, D.; Tuit, K.; Hansen, J.; Kimmerling, A.; Morgan, P.T.; Sinha, R. Guanfacine effects on stress, drug craving and prefrontal activation in cocaine dependent individuals: Preliminary findings. J. Psychopharmacol. 2012, 26, 958–972. [Google Scholar] [CrossRef]
  100. Fox, H.C.; Sofuoglu, M.; Morgan, P.T.; Tuit, K.L.; Sinha, R. The effects of exogenous progesterone on drug craving and stress arousal in cocaine dependence: Impact of gender and cue type. Psychoneuroendocrinology 2013, 38, 1532–1544. [Google Scholar] [CrossRef] [Green Version]
  101. Handelsman, L.; Limpitlaw, L.; Williams, D.; Schmeidler, J.; Paris, P.; Stimmel, B. Amantadine does not reduce cocaine use or craving in cocaine-dependent methadone maintenance patients. Drug Alcohol Depend. 1995, 39, 173–180. [Google Scholar] [CrossRef]
  102. Handelsman, L.; Rosenblum, A.; Palij, M.; Magura, S.; Foote, J.; Lovejoy, M.; Stimmel, B. Bromocriptine for cocaine de-pendence. A controlled clinical trial. Am. J. Addict. 1997, 6, 54–64. [Google Scholar] [PubMed]
  103. Jobes, M.L.; Ghitza, U.E.; Epstein, D.H.; Phillips, K.A.; Heishman, S.J.; Preston, K.L. Clonidine blocks stress-induced craving in cocaine users. Psychopharmacology 2011, 218, 83–88. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  104. Jobes, M.L.; Aharonovich, E.; Epstein, D.H.; Phillips, K.A.; Reamer, D.; Anderson, M.; Preston, K.L. Effects of Prereactivation Propranolol on Cocaine Craving Elicited by Imagery Script/Cue Sets in Opioid-dependent Polydrug Users: A Ran-domized Study. J. Addict. Med. 2015, 9, 491–498. [Google Scholar] [CrossRef] [PubMed]
  105. Johnson, B.A.; Roache, J.D.; Ait-Daoud, N.; Wells, L.T.; Mauldin, J.B. Effects of Isradipine on Cocaine-Induced Subjective Mood. J. Clin. Psychopharmacol. 2004, 24, 180–191. [Google Scholar] [CrossRef]
  106. Johnson, M.W.; Bruner, N.R.; Johnson, P.S.; Silverman, K.; Berry, M.S. Randomized controlled trial of d-cycloserine in cocaine dependence: Effects on contingency management and cue-induced cocaine craving in a naturalistic setting. Exp. Clin. Psychopharmacol. 2020, 28, 157–168. [Google Scholar] [CrossRef]
  107. Kablinger, A.S.; Lindner, M.A.; Casso, S.; Hefti, F.; DeMuth, G.; Fox, B.S.; McNair, L.; McCarthy, B.G.; Goeders, N.E. Effects of the combination of metyrapone and oxazepam on cocaine craving and cocaine taking: A double-blind, randomized, placebo-controlled pilot study. J. Psychopharmacol. 2012, 26, 973–981. [Google Scholar] [CrossRef]
  108. Kampman, K.M.; Volpicelli, J.R.; Mulvaney, F.; Alterman, A.I.; Cornish, J.; Gariti, P.; Cnaan, A.; Poole, S.; Muller, E.; Acosta, T.; et al. Effectiveness of propranolol for cocaine dependence treatment may depend on cocaine withdrawal symptom severity. Drug Alcohol Depend. 2001, 63, 69–78. [Google Scholar] [CrossRef]
  109. Kampman, K.M.; Dackis, C.; Lynch, K.G.; Pettinati, H.; Tirado, C.; Gariti, P.; Sparkman, T.; Atzram, M.; O’Brien, C.P. A double-blind, placebo-controlled trial of amantadine, propranolol, and their combination for the treatment of cocaine dependence in patients with severe cocaine withdrawal symptoms. Drug Alcohol Depend. 2006, 85, 129–137. [Google Scholar] [CrossRef]
  110. Winhusen, T.; Somoza, E.; Harrer, J.; Moore, E.; Ussery, T.; Kropp, F.; Singal, B.; Elkashef, A.; Mojsiak, J. Metyrapone and cocaine: A double-blind, placebo-controlled drug interaction study. Pharmacol. Biochem. Behav. 2005, 80, 631–638. [Google Scholar] [CrossRef]
  111. Lee, M.R.; Glassman, M.; King-Casas, B.; Kelly, D.L.; Stein, E.A.; Schroeder, J.; Salmeron, B.J. Complexity of oxytocin’s effects in a chronic cocaine dependent population. Eur. Neuropsychopharmacol. 2014, 24, 1483–1491. [Google Scholar] [CrossRef] [Green Version]
  112. Leyton, M.; Casey, K.F.; Delaney, J.S.; Kolivakis, T.; Benkelfat, C. Cocaine craving, euphoria, and self-administration: A preliminary study of the effect of catecholamine precursor depletion. Behav. Neurosci. 2005, 119, 1619–1627. [Google Scholar] [CrossRef] [PubMed]
  113. Licata, S.C.; Penetar, D.M.; Ravichandran, C.; Rodolico, J.; Palmer, C.; Berko, J.; Geaghan, T.; Looby, A.; Peters, E.; Ryan, E.; et al. Effects of Daily Treatment With Citicoline: A Double-Blind, Placebo-Controlled Study in Cocaine-Dependent Volunteers. J. Addict. Med. 2011, 5, 57–64. [Google Scholar] [CrossRef] [PubMed]
  114. Malcolm, R.; Kajdasz, D.K.; Herron, J.; Anton, R.F.; Brady, K.T. A double-blind, placebo-controlled outpatient trial of pergolide for cocaine dependence. Drug Alcohol Depend. 2000, 60, 161–168. [Google Scholar] [CrossRef]
  115. Malcolm, R.; LaRowe, S.; Cochran, K.; Moak, D.; Herron, J.; Brady, K.; Hedden, S.; Woolson, R.; Halushka, P. A controlled trial of amlodipine for cocaine dependence: A negative report. J. Subst. Abus. Treat. 2005, 28, 197–204. [Google Scholar] [CrossRef] [PubMed]
  116. Meneses-Gaya, C.D.; Crippa, J.A.; Hallak, J.E.; Miguel, A.Q.; Laranjeira, R.; Bressan, R.A.; Zuardi, A.W.; Lacerda, A.L. Cannabidiol for the treatment of crack-cocaine craving: An exploratory double-blind study. Braz J Psychiatry 2021, 43, 467–476. [Google Scholar] [CrossRef]
  117. Milivojevic, V.; Fox, H.C.; Sofuoglu, M.; Covault, J.; Sinha, R. Effects of progesterone stimulated allopregnanolone on craving and stress response in cocaine dependent men and women. Psychoneuroendocrinology 2016, 65, 44–53. [Google Scholar] [CrossRef] [Green Version]
  118. Modesto-Lowe, V.; Burleson, J.A.; Hersh, D.; Bauer, L.O.; Kranzler, H.R. Effects of naltrexone on cue-elicited craving for alcohol and cocaine. Drug Alcohol Depend. 1997, 49, 9–16. [Google Scholar] [CrossRef]
  119. Mongeau-Pérusse, V.; Brissette, S.; Bruneau, J.; Conrod, P.; Dubreucq, S.; Gazil, G.; Stip, E.; Jutras-Aswad, D. Cannabidiol as a treatment for craving and relapse in individuals with cocaine use disorder: A randomized placebo-controlled trial. Addiction 2021, 116, 2431–2442. [Google Scholar] [CrossRef]
  120. Mooney, M.E.; Schmitz, J.; Moeller, F.G.; Grabowski, J. Safety, tolerability and efficacy of levodopa–carbidopa treatment for cocaine dependence: Two double-blind, randomized, clinical trials. Drug Alcohol Depend. 2007, 88, 214–223. [Google Scholar] [CrossRef] [Green Version]
  121. Maria, M.M.M.-S.; Baker, N.L.; Ramakrishnan, V.; Brady, K.T.; McRae-Clark, A. Impact of acute guanfacine administration on stress and cue reactivity in cocaine-dependent individuals. Am. J. Drug Alcohol Abus. 2014, 41, 146–152. [Google Scholar] [CrossRef]
  122. Nann-Vernotica, E.; Donny, E.; Bigelow, G.E.; Walsh, S.L. Repeated administration of the D 1/5 antagonist ecopipam fails to attenuate the subjective effects of cocaine. Psychopharmacology 2001, 155, 338–347. [Google Scholar] [CrossRef]
  123. Nasser, A.F.; Fudala, P.J.; Zheng, B.; Liu, Y.; Heidbreder, C. A Randomized, Double-Blind, Placebo-Controlled Trial of RBP-8000 in Cocaine Abusers: Pharmacokinetic Profile of RBP-8000 and Cocaine and Effects of RBP-8000 on Cocaine-Induced Physiological Effects. J. Addict. Dis. 2014, 33, 289–302. [Google Scholar] [CrossRef] [PubMed]
  124. Newton, T.F.; Haile, C.N.; Mahoney, J.J.; Shah, R.; Verrico, C.D.; De La Garza, R.; Kosten, T.R. Dopamine D3 receptor-preferring agonist enhances the subjective effects of cocaine in humans. Psychiatry Res. 2015, 230, 44–49. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  125. Petrakis, I.L.; Carroll, K.; Nich, C.; Gordon, L.T.; McCance-Katz, E.F.; Frankforter, T.; Rounsaville, B.J. Disulfiram treatment for cocaine dependence in methadone-maintained opioid addicts. Addiction 2000, 95, 219–228. [Google Scholar] [CrossRef] [PubMed]
  126. Plebani, J.G.; Lynch, K.G.; Yu, Q.; Pettinati, H.M.; O’Brien, C.P.; Kampman, K.M. Results of an initial clinical trial of varenicline for the treatment of cocaine dependence. Drug Alcohol Depend. 2012, 121, 163–166. [Google Scholar] [CrossRef] [Green Version]
  127. Preston, K.; Sullivan, J.T.; Berger, P.; Bigelow, G.E. Effects of cocaine alone and in combination with mazindol in human cocaine abusers. J. Pharmacol. Exp. Ther. 1993, 267, 296–307. [Google Scholar]
  128. Price, K.L.; Baker, N.L.; McRae-Clark, A.L.; Saladin, M.E.; DeSantis, S.M.; Ana, E.J.S.; Brady, K.T. A randomized, placebo-controlled laboratory study of the effects of D-cycloserine on craving in cocaine-dependent individuals. Psychopharmacology 2012, 226, 739–746. [Google Scholar] [CrossRef] [Green Version]
  129. Prisciandaro, J.J.; Myrick, H.; Henderson, S.; McRae-Clark, A.L.; Ana, E.J.S.; Saladin, M.E.; Brady, K.T. Impact of DCS-facilitated cue exposure therapy on brain activation to cocaine cues in cocaine dependence. Drug Alcohol Depend. 2013, 132, 195–201. [Google Scholar] [CrossRef] [Green Version]
  130. Reid, M.S.; Angrist, B.; Baker, S.; Woo, C.; Schwartz, M.; Montgomery, A.; Majewska, D.; Robinson, J.; Rotrosen, J. A placebo-controlled screening trial of celecoxib for the treatment of cocaine dependence. Addiction 2005, 100, 32–42. [Google Scholar] [CrossRef]
  131. Reid, M.S.; Angrist, B.; Ba, S.O.; Ba, J.S.; Schwartz, M.; Rotrosen, J.; Baker, S.A.; Robinson, J.; Leiderman, D.; Montgomery, A.; et al. A Placebo Controlled, Double-Blind Study of Mecamylamine Treatment for Cocaine Dependence in Patients Enrolled in an Opiate Replacement Program. Subst. Abus. 2006, 26, 5–14. [Google Scholar] [CrossRef]
  132. Renshaw, P.F.; Daniels, S.; Lundahl, L.H.; Rogers, V.; Lukas, S.E. Short-term treatment with citicoline (CDP-choline) attenuates some measures of craving in cocaine-dependent subjects: A preliminary report. Psychopharmacology 1999, 142, 132–138. [Google Scholar] [CrossRef] [PubMed]
  133. Rosse, R.B.; Alim, T.N.; Fay-Mccarthy, M.; Collins, J.P.; Vocci, F.J.; Lindquist, T.; Jentgen, C.; Hess, A.L.; Deutsch, S.I. Nimodipine Pharmacotherapeutic Adjuvant Therapy for Inpatient Treatment of Cocaine Dependence. Clin. Neuropharmacol. 1994, 17, 348–358. [Google Scholar] [CrossRef] [PubMed]
  134. Saladin, M.E.; Gray, K.M.; McRae-Clark, A.L.; LaRowe, S.D.; Yeatts, S.D.; Baker, N.L.; Hartwell, K.J.; Brady, K.T. A double blind, placebo-controlled study of the effects of post-retrieval propranolol on reconsolidation of memory for craving and cue reactivity in cocaine dependent humans. Psychopharmacology 2013, 226, 721–737. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  135. Ana, E.J.S.; Prisciandaro, J.J.; Saladin, M.E.; McRae-Clark, A.L.; Shaftman, S.R.; Nietert, P.J.; Brady, K.T. D-cycloserine combined with cue exposure therapy fails to attenuate subjective and physiological craving in cocaine dependence. Am. J. Addict. 2015, 24, 217–224. [Google Scholar] [CrossRef] [Green Version]
  136. Schmitz, J.M.; Green, C.E.; Hasan, K.M.; Vincent, J.; Suchting, R.; Weaver, M.F.; Moeller, F.G.; Narayana, P.A.; Cunningham, K.A.; Dineley, K.T.; et al. PPAR-gamma agonist pioglitazone modifies craving intensity and brain white matter integrity in patients with primary cocaine use disorder: A double-blind randomized controlled pilot trial. Addiction 2017, 112, 1861–1868. [Google Scholar] [CrossRef]
  137. Schmitz, J.M.; Stotts, A.L.; Rhoades, H.M.; Grabowski, J. Naltrexone and relapse prevention treatment for cocaine-dependent patients. Addict. Behav. 2001, 26, 167–180. [Google Scholar] [CrossRef]
  138. Schmitz, J.M.; Mooney, M.E.; Moeller, F.G.; Stotts, A.L.; Green, C.; Grabowski, J. Levodopa pharmacotherapy for cocaine dependence: Choosing the optimal behavioral therapy platform. Drug Alcohol Depend. 2008, 94, 142–150. [Google Scholar] [CrossRef] [Green Version]
  139. Schulte, M.H.; Wiers, R.; Boendermaker, W.J.; Goudriaan, A.E.; Brink, W.V.D.; van Deursen, D.S.; Friese, M.; Brede, E.; Waters, A.J. Reprint of The effect of N-acetylcysteine and working memory training on cocaine use, craving and inhibition in regular cocaine users: Correspondence of lab assessments and Ecological Momentary Assessment. Addict. Behav. 2018, 83, 79–86. [Google Scholar] [CrossRef]
  140. Shoptaw, S.; Kintaudi, P.; Charuvastra, C.; Ling, W. A screening trial of amantadine as a medication for cocaine dependence. Drug Alcohol Depend. 2001, 66, 217–224. [Google Scholar] [CrossRef]
  141. Shoptaw, S.; Yang, X.; Rotheram-Fuller, E.J.; Hsieh, Y.-C.M.; Kintaudi, P.C.; Charuvastra, V.C.; Ling, W. Randomized Placebo-Controlled Trial of Baclofen for Cocaine Dependence: Preliminary effects for individuals with chronic patterns of cocaine use. J. Clin. Psychiatry 2003, 64, 1440–1448. [Google Scholar] [CrossRef]
  142. Winhusen, T.; Somoza, E.; Sarid-Segal, O.; Goldsmith, R.J.; Harrer, J.M.; Coleman, F.S.; Kahn, R.; Osman, S.; Mezinskis, J.; Li, S.-H.; et al. A double-blind, placebo-controlled trial of reserpine for the treatment of cocaine dependence. Drug Alcohol Depend. 2007, 91, 205–212. [Google Scholar] [CrossRef] [PubMed]
  143. Woodcock, E.A.; Lundahl, L.H.; Khatib, D.; Stanley, J.A.; Greenwald, M.K. N -acetylcysteine reduces cocaine-seeking behavior and anterior cingulate glutamate/glutamine levels among cocaine-dependent individuals. Addict. Biol. 2020, 26, e12900. [Google Scholar] [CrossRef] [PubMed]
  144. Somoza, E.C.; Winship, D.; Gorodetzky, C.W.; Lewis, D.; Ciraulo, D.A.; Galloway, G.P.; Segal, S.D.; Sheehan, M.; Roache, J.D.; Bickel, W.K.; et al. A Multisite, Double-blind, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Vigabatrin for Treating Cocaine Dependence. JAMA Psychiatry 2013, 70, 630–637. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  145. Reid, M.S.; Mickalian, J.D.; Delucchi, K.L.; Hall, S.M.; Berger, S. An acute dose of nicotine enhances cue-induced cocaine craving. Drug Alcohol Depend. 1998, 49, 95–104. [Google Scholar] [CrossRef]
  146. Yonkers, K.A.; Forray, A.; Nich, C.; Carroll, K.M.; Hine, C.; Merry, B.C.; Shaw, H.; Shaw, J.; Sofuoglu, M. Progesterone for the reduction of cocaine use in post-partum women with a cocaine use disorder: A randomised, double-blind, placebo-controlled, pilot study. Lancet Psychiatry 2014, 1, 360–367. [Google Scholar] [CrossRef] [Green Version]
  147. Kampman, K.M.; Dackis, C.; Pettinati, H.M.; Lynch, K.G.; Sparkman, T.; O’Brien, C.P. A double-blind, placebo-controlled pilot trial of acamprosate for the treatment of cocaine dependence. Addict. Behav. 2011, 36, 217–221. [Google Scholar] [CrossRef] [Green Version]
  148. LaRowe, S.D.; Kalivas, P.W.; Nicholas, J.S.; Randall, P.K.; Mardikian, P.N.; Malcolm, R.J. A double-blind placebo-controlled trial of N-acetylcysteine in the treatment of cocaine dependence. Am. J. Addict. 2013, 22, 443–452. [Google Scholar] [CrossRef] [Green Version]
  149. Lu, L.; Grimm, J.W.; Hope, B.T.; Shaham, Y. Incubation of cocaine craving after withdrawal: A review of preclinical data. Neuropharmacology 2004, 47, 214–226. [Google Scholar] [CrossRef]
  150. Castells, X.; Cunill, R.; Pérez-Mañá, C.; Vidal, X.; Capellà, D. Psychostimulant drugs for cocaine dependence. Cochrane Database Syst. Rev. 2016, 9, CD007380. [Google Scholar] [CrossRef]
  151. United Nations Office on Drugs and Crime. World Drug Report 2020 (Sales No. E. 20). Available online: https://wdr.unodc.org/wdr2020/index2020.html (accessed on 10 November 2022).
  152. European Monitoring Centre for Drugs and Drugs Addiction.Treatment for cocaine dependence: Reviewing current evidence. 2014. Available online: https://www.emcdda.europa.eu/system/files/publications/2726/POD2014_Treatment%20for%20cocaine%20dependence.pdf (accessed on 10 November 2022).
  153. Schottenfeld, R.S.; Pakes, J.; Ziedonis, D.; Kosten, T.R. Buprenorphine: Dose-related effects on cocaine and opioid use in cocaine-abusing opioid-dependent humans. Biol. Psychiatry 1993, 34, 66–74. [Google Scholar] [CrossRef]
  154. Montoya, I.D.; Montoya, M.I.D.; Gorelick, D.A.; Preston, K.; Schroeder, J.R.; Umbricht, A.; Cheskin, L.J.; Contoreggi, C.; Johnson, R.E.; Fudala, P.J. Randomized trial of buprenorphine for treatment of concurrent opiate and cocaine dependence. Clin. Pharmacol. Ther. 2004, 75, 34–48. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  155. Foltin, R.W.; Fischman, M.W. Effects of methadone or buprenorphine maintenance on the subjective and reinforcing effects of intravenous cocaine in humans. J. Pharmacol. Exp. Ther. 1996, 278, 1153–1164. [Google Scholar] [PubMed]
  156. Hollander, J.A.; Pham, D.; Fowler, C.D.; Kenny, P.J. Hypocretin-1 receptors regulate the reinforcing and reward-enhancing effects of cocaine: Pharmacological and behavioral genetics evidence. Front. Behav. Neurosci. 2012, 6, 47. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  157. Gentile, T.A.; Simmons, S.J.; Watson, M.N.; Connelly, K.; Brailoiu, E.; Zhang, Y.; Muschamp, J.W. Effects of Suvorexant, a Dual Orexin/Hypocretin Receptor Antagonist, on Impulsive Behavior Associated with Cocaine. Neuropsychopharmacology 2017, 43, 1001–1009. [Google Scholar] [CrossRef] [Green Version]
  158. Levin, F.R.; Mariani, J.J.; Pavlicova, M.; Choi, C.J.; Mahony, A.L.; Brooks, D.J.; Bisaga, A.; Dakwar, E.; Carpenter, K.M.; Naqvi, N.; et al. Extended release mixed amphetamine salts and topiramate for cocaine dependence: A randomized clinical replication trial with frequent users. Drug Alcohol Depend. 2020, 206, 107700. [Google Scholar] [CrossRef]
  159. Wee, S.; Vendruscolo, L.F.; Misra, K.K.; Schlosburg, J.E.; Koob, G.F. A Combination of Buprenorphine and Naltrexone Blocks Compulsive Cocaine Intake in Rodents Without Producing Dependence. Sci. Transl. Med. 2012, 4, 146ra110. [Google Scholar] [CrossRef]
Brainsci 12 01546 g001 550
Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Flow Diagram.
Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Flow Diagram.
Brainsci 12 01546 g001
Table
Table 1. Characteristics and main findings of the studies included in the systematic review–Antidepressants.
Table 1. Characteristics and main findings of the studies included in the systematic review–Antidepressants.
Author, Year, CountryN (Sample); Age (Mean); Gender (M:F); Search for Treatment (Y: Yes; N: No); Setting (O: Outpatient; I: Inpatient; M: Mixed); Follow-upDependence; Route of Cocaine Use (S: Smoked, I: Inhaled, IV: Intravenous, O: Oral); Cocaine Use Status (C: Current Use; A: Abstinent)Craving Assessment InstrumentPharmacotherapy and Duration; Non-Pharmacological InterventionOutcomes (AG: Active Group; PG: Control/Placebo Group)Dropout %(Number); Intention to Treat (ITT) Analysis (Y: Yes; N: No)
Afshar et al., 2012, USA [19]24; 45; 17:7; NA; O; 12 weeksCocaine dependence and major depression (DSM-IV); S, I; CCocaine Craving Scale (CCS); Cocaine Craving Questionnaire (CCQ)Oral mirtazapine (MTZ) 45 mg or placebo (PBO) daily for 12 weeks; weekly hour-long sessions involving (manual guided) relapse prevention counselingCCS: The time effect for the strength of craving score was significant for the placebo group [F(10,91.2) = 4.6, p < 0.0001], but not for the mirtazapine group (Baseline: PBO: 52.6 (29.8), MTZ: 51.1 (22.8);endpoint: PBO: 30.4 (27.3), MTZ: 45.0 (15.5)); CCQ: neither the treatment effect nor the treatment × time interaction was significant, and the within-group time effects were also insignificant (Baseline: PBO: 168.6 (56.9), MTZ: 184.6 (96.0); endpoint: PBO: 140 (57.4), MTZ: 156.4 (35.2))NA; NA
Arndt et al., 1992, USA [20]79; 41; 79:0; NA; O; 12 weeks of intervention + contacts after 6 monthsCocaine dependence (DSM-III) among methadone-maintained patients; S, I, IV; CCocaine Craving Scale (CCS)Oral desipramine (DSP) 250–300 mg or placebo (PBO) daily and regular methadone treatment for 12 weeks; NACCS: Cocaine craving dropped significantly from 13 to 8 (on a scale of 1 to 20), but there was no significant difference between groups (Baseline: PBO: 12, DSP: 13; endpoint: PBO: 7, DSP: 8)25% (20); NA
Batki et al., 1996, USA [21]32; 34; 21:11; Y; O; 12 weeksCocaine dependence (DSM-IIIR); S, IV; CQuantitative Cocaine Inventory (QCI)Oral fluoxetine 40 mg or placebo daily for 12-week; NAQCI: No differences in craving were found between the two groups over weeks59% (19); NA
Buydens-Branchey et al., 1998, USA [22]19; NA; 19:0; Y; I; 1 dayCocaine dependence (DSM-IV); NA; AVAS (100-mm line where 0 indicated that the chances were nil and 100 indicated that they were certain they would use cocaine)Single dose of oral fenfluramine 60 mg or placebo; NAVAS: a significantly greater craving decline after fenfluramine administration (p <0.05) compared to placeboNA; NA
Campbell et al., 2003, USA [23]146; 33; 102: 44; NA; O; 8 weeksCocaine abuse (Psychiatric Diagnostic Interview-Revised- PDI-R); NA; NAHalikas-Crosby Drug Impairment Rating Scale (Hal-DIRS)Oral desipramine 200 mg, carbamazepine 800 mg or placebo daily for 8 weeks; therapyHal-DIRS: subjects improved over time, but there was no statistically significant difference between groups65% (95); Y;
Ciraulo, Knapp et al., 2005, USA [24]69; 40; 49:20; NA; O; 8 weekscocaine dependence and had Hamilton Depression Scores of 12 or higher (DSM-IV); S, I, IV; CCocaine Craving Scale (CCS)Oral nefazodone 400 mg daily or placebo for 8 weeks; individual counselingCCS: significant reduction in craving strength for both groups (<0.0001), but more for nefazodone (p = 0.049). Decrease in intensity was significant in both nefazodone (p < 0.0001) and placebo (p < 0.0001) groups26% (18)
Ciraulo, Sarid-Segal et al., 2005, USA [25]S1: 65; 40; 47:18; NA; O; 8 weekS2: 60; 43; 43:17; NA; O; 8 weeksCocaine dependence (DSM-IV); NA; CS1 and S2: Brief Substance Craving Scale (BSCS)S1: oral paroxetine 20 mg daily or pentoxifylline 400 mg three times a day or riluzole 50 mg twice daily or placebo twice daily for 8 weeks; cognitive behavioral counseling; S2: oral venlafaxine (50 mg three times a day) or pramipexole (0.5 mg three times a day) or placebo, three times daily for 8 weeks; cognitive behavioral counselingS1 and S2: BSCS: Changes between baseline and end-point values were not found to differ among the placebo and the active medication groups, but significant within-group decreases in mean scores in all groupsS1: 11% (7); S2: 36.6% (22); NA
Gawin et al., 1989, USA [26]72; 29; 55:17; Y; O; 6 weeksCocaine dependence (DSM-III-R); S, I, IV; CCocaine Use Inventory and Craving Scale (−10 represents no craving; 0, about the usual craving; and 10, more craving than ever)Oral desipramine hydrochloride 2,5 mg/Kg or lithium carbonate 600 mg or placebo daily for 6 weeks; weekly individual psychotherapyCraving: statistically significant differences in craving appearing in the desipramine-treated subjects by week 4 (p < 0.0001)54% (39); NA
Grabowski et al., 1995, USA [27]S1: 155; 32; 112:43; 2-week runup+ 12-week intervention; S2: 21; 39; 16:5; NA; O; 2-week stabilization + 8 weeks of interventionS1: cocaine-dependent (DSM-III); S2: cocaine and opiate dependent in methadone maintenance treatment (DSM-III-R); NA; NAS1 and S2: Desire to Use Drugs Inventory (DUDI)S1: Oral fluoxetine 0, 20, or 40 mg daily or placebo; NA. S2: oral fluoxetine 20 mg or placebo, in addition to and 65 to 80 mg of methadone daily; individual therapy sessionsS1: DUDI: scores being highest at intake and diminishing during treatment (F = 10.9, df = 3147, p < 0.01). Fluoxetine produced no significant effect on “desire to use drug” over time by dose (f ratio < 1.0); S2: DUDI: Fluoxetine produced no significant decrease in craving in any medication groupS1: 55% (85); S2: 43% (10); NA
Harris et al., 2004, USA [28]29; 40; 20:2; NA; M; 11 weeksCocaine dependence (DSM-IV); NA; NAWithin Session Rating Scale (VAS 100 mm: ‘‘desire to use’’ and ‘‘likely to use’’)Oral fluoxetine 40 mg or placebo daily for 11 weeks; NAVAS: Desire to use: no significant difference between groups; Likely to use: significant increase (p < 0.03) for de fluoxetine group24% (7); N
Kolar et al., 1992, USA [29]22; 35; 19:3; NA; O; 12 weeksCocaine dependence in methadone maintenance clients (DSM-III-R); S, IV; CSelf-report craving (0=“Not at all” to 20= “More than ever” over past 7 days)Oral desipramine 200 mg or amantadine 200 mg or placebo for 12 weeks; weekly counseling sessionsCraving: significantly reduced over time in all three groups. However, there were no differences between groups on these measures (Time effect: F18.519 df 12/228 p <0.01; Group effect: F 0.9321 df 2/19 p N.S.)32% (7); NA
Kosten et al., 1992, USA [30]94; 32; 45:49; NA; O; 12 weeksOpioid and cocaine dependence (DSM-III-R); NA; NAVAS (analogue scale, with scores ranging from 0 (no craving) to 20 (most craving in life))Oral amantadine hydrochloride300 mg or desipramine hydrochloride 150 mg or placebo daily for 12 weeks; weekly group relapse prevention therapyVAS: Craving showed little change over the course of this trial and no difference across medication groups21% (20); NA
McDowell et. al, 2005, USA [31]111; 36; 83:28; Y; O; 1-week single blind lead-in placebo + 12 weeks of interventionCocaine dependence and major depression or dysthymia (DSM-III-R); S, I, IV; NASelf-report cocaine craving (TLFB)Oral desipramine up to 300 mg or placebo daily for 12 weeks; weekly individual manual-guided relapse prevention therapyTLFB: no significant differences between the treatment groups in self-reported cocaine craving58% (64); Y
Nanni- Alvarado et al., 2021, Mexico [32]100; 28; 100:0; NA; M;12 weekDSM-IV criteria for cocaine use disorder; NA; ACocaine Craving Questionnaire (CCQ-G)Oral mirtazapine 30 mg/kg or plcebo daily for 12 weeks; NACCQ: group treated with mirtazapine showed a significant decrease in mean
craving compared to the placebo group (p < 0.01)		36% (36); N
Oliveto et al., 1995, USA [33]21; 33; 11:10; NA; O; 12 weeksOpioid-dependent and at least one positive cocaine urine and/or reported use of at least 14 g of cocaine over the 3-month period immediately preceding; NA; CVAS: intensity of their desire for cocaine at the time they completed the form as well as in the past week on a scale from 0 (none at all) to 24 (more than ever)Oral buprenorphine 8 mg plus either oral desipramine 150 mg, amantadine 300 mg, or fluoxetine 60 mg daily for 12 weeks; weekly group relapse preventionVAS: craving reduced, but did not differ between groups58% (10); NA
Passos et al., 2005, Brazil [34]210; 31; 194:16; NA; O; 10 weeksCocaine dependence (DSM-IV); NA; NAVAS: rated by the subject from 0 cm (no craving) to 10 cm (maximum craving)Oral nefazodone 300 mg or placebo daily for 10 weeks; weekly individual psychotherapyVAS: average craving did not differ between groups: 4.13 9 (nefazodone) and 4.17 (placebo)79% (166); NA
Shoptaw et al., 2008, USA [35]70; 37; 59:11; Y; O; 16 weeks intervention + 4 weeks observationCocaine abuse or dependence (DSM-IV); S, I, IV, O; C;Cocaine Craving Scale (CCS)Oral bupropion 300 mg or placebo daily for 16 weeks; cognitive behavioral therapy for 16 weeksCCS: Cocaine craving decreased in both groups during the trial, although there were no statistically significant differences (p = 0.419)82% (58); Y
Winstanley et al., 2011, USA [36]145; 38; 79: 66; Y; O; 3 weeks of methadone+ 18 weeks of intervention + 12 weeks observationCocaine dependence and opioid dependence in treatment with methadone (DSM-IV); NA; NAVASOral fluoxetine 60 mg or placebo daily for 18 weeks; psychosocial counseling (individual and group)VAS: There were no statistically significant between-group differences over time for craving scores35% (51); Y
S1: study 1; S2: study 2.
Table
Table 2. Characteristics and main findings of the studies included in the systematic review–Psychostimulants.
Table 2. Characteristics and main findings of the studies included in the systematic review–Psychostimulants.
Author, Year, CountryN (Sample); Age (Mean); Gender (M:F); Search for Treatment (Y: Yes; N: No); Setting (O: Outpatient; I: Inpatient; M: Mixed); Follow-upDependence; Route of Cocaine use (S: Smoked, I: Inhaled, IV: Intravenous, O: Oral); Cocaine Use Status (C: Current Use; A: Abstinent)Craving Assessment InstrumentPharmacotherapy and Duration; Non-Pharmacological InterventionOutcomes (AG: Active Group; PG: Control/Placebo Group)Dropout %(Number); Intention to Treat (ITT) Analysis (Y: Yes; N: No)
Alim et al., 1995, USA [37]60; 33; NA; NA; I; 1-week baseline + 2 weeks of interventionCocaine dependence (DSM-III-R); S; NAQuestionnaire of Cocaine Urges (QCU); VASOral diethylpropion 25, 50, 75 mg or 75 mg sustained release or placebo daily for 2 weeks; therapyVAS: decrease in craving from baseline to end of intervention: F (1,45) = 27,39, p < 0.001; but no significant group differences; QCU: scores were higher in baseline than in the first 2 weeks of trial, but with no interaction with the groups16,6% (10); NA
Anderson et al., 2009, USA
[38]		210; 42; 148:59; Y; O; 12 weeks of intervention + 4 weeks of observationCocaine dependence (DSM-IV) NA; CBrief Substance Craving Scale (BSCS); Cocaine Craving Questionnaire (CCQ)Oral modafinil 200 mg or 400 mg or placebo daily for 12 weeks; one hour of individual weekly cognitive behavioral therapyBSCS: craving declined on average within each active arm, and this difference from placebo was nominally significant for 200 mg (p = 0.04) but not for 400 mg (p = 0.90); CCQ: No significant effect on total score was noted, however, the sub-domains “Anticipation” (p = 0.04) and “Relief” (p = 0.03) were significant with treatment of 200 mg modafinil.40% (75); NA
Buydens-Branchey et al., 1997, USA [39]31; 37; 31:0; Y; I; 2 days of intervention + 2 days intervalcocaine dependence (DSM-III-R) S, I; AVAS (chances they would use cocaine if they were not in the hospital and had unlimited financial resources. They were asked to draw a mark on a 100-mm line where 0 indicated that the chances were nil and 100 indicated that they were certain they would use cocaine)Oral metachlorophenylpiperazine (m-CPP) 0.5 mg/kg of body weight or placebo for 2 days (separated by 48 h); NACraving: Patients’ craving for cocaine was found to decrease significantly (20%) after the administration of m-CPP (drug effect (F [1,1 = 41 2 5.4; p < 0.001))NA; NA
Cantilena et al., 2012, USA [40]20; 40; 18:2; N; I; 2 weeks intervention + observation after 2 weeksCocaine abuse or dependence (DSM-IV); NA; CBrief Substance Craving Scale (BSCS)Oral atomoxetine up to 100 mg or placebo daily for 2 weeks; NABSCS: craving reduced over time, but there were no significant differences between the atomoxetine and placebo groups on any days of assessment20% (4); NA
Cornish et al., 2001, USA [41]80; 38; 80:0; Y; O; 2 weeks placebo lead in + 4 weeks intervention + 4 weeks observationCocaine dependence (DSM-IIIR); NA; CVAS (100-mm line their maximum level of craving over the previous 48-h period)Oral ritanserin 10 mg or placebo daily for 4 weeks; counselingVAS: neither the main effects nor the time by group interaction approached significance24% (19); NA
Dackis et al., 2003, USA [42]10; 44; 10:0; NA; O; 4 daysCocaine dependence (DSM-IV); S; CVAS (cocaine craving)Oral modafinil 200 mg, or 400 mg or placebo daily for 4 days; NAVAS: within each period, there was not a significant treatment effect30% (3); NA
Dackis et al., 2005, USA [43]62; 44; 44:16; Y; O; 8 weeks intervention + 1-week observation;Cocaine dependence (DSM-IV); S; CBrief Substance Craving Scale (BSCS); Cocaine Craving Questionnaire (CCQ)Oral modafinil 400 mg or placebo daily for 8 weeks; twice-weekly cognitive behavioral therapyBCSC, CCQ: no significant treatment group differences in the BCSC, or in the CCQ total score (Z-score¼0.76, p¼0.45)8% (5); Y
Dackis et al., 2012, USA [44]210; 45; 157:53; Y; O; 8 weeksCocaine dependence (DSM-IV); NA; CBrief Substance Craving Scale (BSCS)Oral modafinil 200 mg or 400 mg or placebo daily for 8 weeks; once-weekly cognitive behavioral therapyBSCS: no treatment group differences11,4% (24); Y
Ehrman et al., 1996, USA [45]45; 38; 45:0; Y; O; 2 weeks screening + 4 weeks interventionCocaine dependence (DSM-III); S, I; CVAS: scale of O-10Oral ritanserin 10 mg or placebo daily for 4 weeks; NAVAS: ritanserin had no effect on cue-induced cravingNA; NA
Goudriaan et. al, 2013, Netherlands [46]29; 39; NA; Y; O; single-dose+ 1-week observationCocaine dependence (DSM-IV); NA; ACocaine Urge Questionnaire (CUQ)Single dose of modafinil 200 mg or placebo; NACUQ: no significant changes in craving scores in the cocaine dependent were present in the modafinil versus the placebo condition (p = 0.39)NA; Y
Grabowski et al., 1997, USA [47]49; 34; 38:11; NA; O; 2-week intake period + 11-week medication trial+ 2-week observationCocaine dependence (DSM-IIIR); S, I; NA;Self -report cravingOral methylphenidate 45 mg or placebo daily for 11 weeks; therapy sessions 1 h/weekNo significant differences between the two groups51% (25); NA
Greenwald et al., 2010, USA [48]13; NA; 6:2; N; I; 3 weeksOpioid dependence and cocaine dependence (DSM-IV); S; CCocaine Craving Questionnaire (CCQ); VAS (0–100: Want Drug Again)Oral d-amphetamine 30 or 60 mg sustained release (SR-AMP) or placebo daily for 3 days, followed by 4 conditions: cocaine (COC 100 mg+ saline), hydromorphone (COC 4 mg +HYD 24 mg), ‘speedball’ (COC 100 mg +HYD 24 mg) and placebo (COC 4 mg + saline); NACCQ: IG presented no significant reduction relative to PG (F 3.41 p (0.07)); VAS (Want drug again): IG presented a significant reduction relative to PG (F 8.48 p (0.01)38% (5); N
Johns et al., 2021, USA [49]25; 51; 11:2; N; M; 19 daysDSM-5 criteria for cocaine use disorder; S or IV; CVisual Analogue Scale (VAS)Oral lorcaserin 20 mg or placebo daily for 19 days; NAVAS: there was a decrease in “I am craving” (p, 0.0001) for lorcaserin48% (12); N
Johnson et al., 1997, USA [50]65; 36; 55:10; Y; O; 2 weeks single-blind+ 4 weeks intervention+ 4 weeks observationCocaine dependence (DSM-IIIR); NA; NAVASOral ritanserin 10 mg or placebo daily for 4 weeks; psychoeducational programVAS: reduction in craving in 66.4% and 32.5% for the placebo and ritanserin groups, respectively at end of intervention27% (18); Y
Kampman et al., 2015, USA [51]94; 47; 76:18; Y; O; 8 weeksCocaine dependence (DSM-IV); S; CBrief Substance Craving Scale (BSCS)Oral modafinil 300 mg or placebo daily for 8 weeks; weekly individual cognitive behavioral therapyBSCS: placebo group was significantly more likely to report higher levels of craving than the modafinil group for intensity (OR = 2.04, 95% Ci = (1.06, 3.92), p = 0.03) and duration (OR = 1.89, 95% Ci = (1.06, 3.38), p = 0.03); there was a similar effect for frequency (OR = 1.51, 95% Ci = (0.84, 2.73)24% (23); Y
Karila et. Al, 2016, France [52]27; 38; 27:0; Y; I; 12 weeksCocaine dependence (DSM-IV); NA; CCocaine Craving Questionnaire (10-item CCQ brief)Oral modafinil 400 mg/day for 26 days, then 300 mg/day for 30 days, and 200 mg/day for 31 days or placebo; NACCQ: No therapeutic advantage of modafinil 400 mg/day was detected during hospitalization18% (5); NA
Levin et al., 2007, USA [53]106; 37; 88:18; Y; O; 14 weeksCocaine dependence and attention deficit hyperactivity disorder (ADHD) (DSM-IV); S, I; CVAS (craving during the last 24 h: “1” (very little) to “100” (very much))Oral sustained-release methylphenidate 40 mg or placebo for 14 weeks; weekly individual cognitive behavioral therapyVAS: Although both groups significantly reduced their craving severity over time (Z = −5.11, p < 0.001), there were no significant group or group by time differences56% (59); Y
Mooney et al., 2009, USA [54]82; 36; 54:28; Y; O; 8 weeksCocaine dependence (DSM-IV); NA; CCocaine craving scale (CCS)Oral immediate release (IR) methamphetamine 30 mg or sustained release (SR)methamphetamine 30 mg or placebo daily for 8 weeks; 4 weeks counseling followed by 4 weeks of counseling plus a contingency management procedureCCS: SR group reported less craving than the placebo group, t (36.3) = 2.49, p = 0.045168% (83); Y
Mooney et al., 2015, USA [55]43; 45; 35:8; Y; O; 14 weeksCocaine dependence (DSM-IV); NA; CVASOral lisdexamphetamine (LDX) 70 mg or placebo daily for 14 weeks; weekly manual-based, cognitive-behavioral therapy (CBT)VAS: those receiving LDX reported significantly less craving for cocaine than participants receiving placebo F(1, 62.6) = 5.94, p = 0.0176, (Placebo, M = 28.7, SE = 3.21; LDX, M = 17.5, SE = 3.30)36% (16); Y
Nuijten et al., 2016, Netherlands [56]73; 49; 66:7; NA; O; 12 weeksCocaine dependence (DSM-IV) and heroin assisted treatment; S; CVAS (0–20)Oral sustained-release dexamphetamine 60 mg or placebo daily, in addition to co-prescribed methadone and diacetylmorphine (max 150 mg) for 12 weeks; NAVAS: significant changes in craving from baseline (Wald = 52·36; p < 0·001), but no significant group differences (Wald = 6·52; p = 0·011)11% (8); Y
Perry et al., 2004, USA [57]24; 38; 23:1; NA; O; 6 weeksSchizophrenia or schizoaffective disorder and cocaine abuse or dependence (DSM-III); NA; NAVASOral mazindol (MZD) 6 mg or placebo (PBO) daily, in addition to their current antipsychotic medication for 6 weeks; cognitive-behavioral therapyNo significant effects were observed in craving: Baseline (Mean (SD)): PBO: 25.38 (29.12) MZD: 28.64 (29.98); Endpoint: PBO:32.14 (35.69) MZD: 13.17 (30.33)16,6% (4); NA
Pirtle et al., 2019, USA [58]11; 41; 11:0; N; M; 5 days of procedure, health status check 3 days after dischargeCocaine Use Disorder (DSM-V); S, IV; CVAS: 100 mm scroll bar marked from 0 (‘not at all’) to 100 (‘extremely) to indicate: ‘How much do you want to use cocaine?’Two doses of oral lorcaserin 10 mg or placebo, separated by 24 h, followed by intravenous cocaine or placebo; NALorcaserin treatment decreased craving following intravenous placebo [F(1, 214) = 15.8, p < 0.001] but not after cocaine18% (2); N
Roache et al., 2000, USA [59]S1: 57, 36, 45:12, NA, 11 weeks; S2:12, 37, 10:2, O, 1 weekCocaine dependence (self-report); NA; CVAS: 100-mm lines ranging from “not at all” to “extremely” for “am craving cocaine,” “desire to use cocaine,” “would use cocaine,” and “want to buy cocaine.”S1: Oral methylphenidate 45 mg daily dose for 11 weeks; NAS2: Oral methylphenidate (15, 30, and 60 mg) followed by placebo for 1 week; NA. S1: found neither positive nor negative influences of methylphenidate on treatment outcome; S2: found neither positive nor negative influences of methylphenidate on treatment outcome.S1: 58% (33);.S2: NA; NA;
Santos et al., 2021, USA [60]22; 39; 22:0; Y; O; 12 weeksDSM-5 criteria for mild to severe cocaine use disorder; S and I; CVisual Analogue Scale (VAS)Oral extended release lorcaserin 20 mg or placebo daily for 12 week; NAVAS: significant treatment
effects in craving (p> 0.09)		14% (3); Y
Schubiner et al., 2002, USA [61]48; 36; 43:5; Y; O; 12 weeksAttention-deficit/hyperactivity disorder (ADHD) and cocaine dependence (DSM-IV); NA; NACocaine Craving Questionnaire (CCQ)Oral methylphenidate up to 90 mg or placebo daily for 12 weeks; twice-weekly cognitive-behavioral group therapy (CBT)CCQ: there were no group differences in cocaine craving47% (23); NA
Shearer et al., 2003, Australia [62]30; 28; 16:14; NA; O; 14 weekscocaine dependence (DSM-IV); IV; CVASOral dexamphetamine 60 mg or placebo daily for 14 weeks; NAVAS: no significant between-group differences; within-group changes were in favor of the treatment group and reached significance for cocaine craving (p < 0.01)64% (19); Y
Stine et al., 1995, USA [63]43; 35; 37:6; NA; O; 6 weeksCocaine dependence (DSM-IIIR); NA; CVAS (5-point analog scale)Oral mazindol 2 mg or placebo daily for 6 weeks; weekly group counselingVAS: craving was not significantly affected by mazindol (drug: df = 1,41; F = 1.8; p = 0.2, time: df = 6,41; F = 10.4; p = 0.001, drug/time interaction: df = 6,41; F = 0.7; p = 0.6) although a decrease with time is observed58% (25); NA
Walsh et al., 2013, USA [64]50; 43; 36:14; Y; O; 12 weeks of treatment+ follow up after 12 weeksCocaine dependence (DSM-IV); S; CCocaine Craving Scale (CCS)Oral atomoxetine 80 mg or placebo daily for 12 weeks; weekly counseling + cognitive behavioral therapyCCS: During the trial, there was a significant group×time interaction (F(11,310) = 1.99; p = 0.03) for “All I want to use now is cocaine” and for “Nothing would be better than using coke right now” (F= 2.37; p= 0.008). Examination of the data suggest that these findings were not due to systematic changes over time in craving for either group; rather the placebo group reported slightly higher scores reliably throughout the trial and for one week (Week 11) the atomoxetine group reported higher scores (creating the interaction) which declined the following week. No other differences on craving items were observed.44% (22); Y
S1: study 1; S2: study 2.
Table
Table 3. Characteristics and main findings of the studies included in the systematic review–Antipsychotics.
Table 3. Characteristics and main findings of the studies included in the systematic review–Antipsychotics.
Author, Year, CountryN (Sample); Age (Mean); Gender (M:F); Search for Treatment (Y: Yes; N: No); Setting (O: Outpatient; I: Inpatient; M: Mixed); Follow-upDependence; Route of Cocaine Use (S: Smoked, I: Inhaled, IV: Intravenous, O: Oral); Cocaine Use Status (C: Current Use; A: Abstinent)Craving Assessment InstrumentPharmacotherapy and Duration; Non-Pharmacological InterventionOutcomes (AG: Active Group; PG: Control/Placebo Group)Dropout %(Number); Intention to Treat (ITT) Analysis (Y: Yes; N: No)
Akerele et al., 2007, USA [65]28; 36; 25:3; NA; O; 14-weeksCurrent cocaine and/or marijuana abuse or dependence and schizophrenia or schizoaffective disorder (DSM-IV); S, I; CCocaine Craving Report (CCR)Oral olanzapine 5–20 mg or oral risperidone 3–9 mg daily for 10 weeks; weekly psychotherapyCCR: there were no significant differences between the groups in terms of cocaine craving over time43% (12); NA
Beresford et al., 2017, USA [66]44; 48; 31:13; Y; O; 8 weeks of intervention + 2 weeks observation;Cocaine dependence and schizophrenia (DSM-IV); NA; CBrief Substance Craving Scale (BSCS)Oral aripiprazole 10–30 mg or perphenazine 12–24 mg daily for 8 weeks; subjects were given the option to attend group behavioral therapy session weeklyBSCS: Contrasting weeks 3 to 5 vs 6 to 8 revealed significant late reductions in craving with aripiprazole. On the respective 5 points subscales, craving intensity decreased by 1.53 ± 0.43 (p < 0.0005) points, craving frequency by 1.4 ± 0.40 (p > 0.0004) points, and craving duration by 1.76 ± 0.44 (p > 0.0001) pointsNA; NA
Hamilton et al., 2009, USA [67]48; 46; 48:0; Y; O; 16 weeks intervention + 4 weeks observationCocaine dependence (DSM-IV); S, I, IV, O; CCraving QuestionnaireOral olanzapine 2,5–20 mg or placebo daily for 16 weeks; psychotherapeutic and educational groupsCraving Questionnaire: significant within-subjects (time) effects, but there were no significant differences between the olanzapine and placebo groupsNA; NA
Kampman et al., 2003, USA [68]30; 40; 22:8; Y; O; 12 weeksCocaine dependence (DSM-IV); S, I, IV; CBrief Substance Craving Scale (BSCS)Oral olanzapine 10 mg or placebo daily for 12 weeks; twice-weekly individual cognitive-behavioralBSCS: significant decline over the 12 weeks: duration (t//3.16, p/0.002); frequency (t//2.94, p/0.004), and intensity (t//2.93, p/0.004). There was no medication effect on either duration (t//0.04, p/0.97), frequency (t/0.50, p/0.62), or intensity (t//0.39, p/0.7)10% (3); NA
Loebl et al., 2008, USA [69]31; 43; 31:0; NA; O; 12 weeksCocaine dependence (DSM-IV); NA; CMinnesota Cocaine Craving Scale (MCCS)Intramuscular risperidone 25 mg or placebo every other week for 12 weeks; NAMCCS: craving reduced in both groups, but with no difference between themNA; NA
Lofwall et al., 2014, USA [70]34; 35; 19:2; N; I; 32 daysSelf-report use; S; CVAS: “Desire for Cocaine”Oral aripiprazole 2 or 10 mg or placebo daily for 32 days; NANo significant group effects were observed40% (13); NA
Moran et al., 2017, USA [71]18; 45; 17:1; Y; O; 12 weeks intervention + 29 weeks of buprenorphine treatmentDependence on opioids, current cocaine use on at least 3 of the last 30 days, lifetime cocaine-use duration of at least one year; S, I, IV; C;Ecological momentary assessment (EMA): participants answered craving questions with the response options “NO!!”, “no??”, “yes??”, and “YES!!”Oral aripiprazole 15 mg or placebo daily for 12 weeks; weekly session of individual counselingEMA: in randomly prompted EMA entries craving was not reported frequently in either group but tended to be reported more often in the aripiprazole group, F (1,13) = 2.91, p =0.11, effect = 0.43, 95% CI = −.08–0.76. Almost all participants in the aripiprazole group reported craving at least once22% (4); Y
Reid, Casadonte et al., 2005, USA [72]63; 39; 50:13; Y; O; 8 weeksCocaine dependence (DSM-IV); S, I, IV; CCocaine Craving Questionnaire general (CCQ-general); Brief Substance Craving Scale (BSCS)Oral olanzapine 10 mg, valproate 1500 mg, coenzyme Q10 200 mg, and L-carnitine 500 mg combination or placebo daily for 8 weeks; cognitive behavioral counselingCCQ: significant treatment effect (p < 0.05), in which the olanzapine group showed significantly higher craving than placebo at week 8 (p < 0.05); BSCS: scores for cocaine craving decreased in all groups by the end of treatment; however, olanzapine group experienced a weaker reduction in cocaine craving at the last clinic visit (p < 0.05);42% (29); NA;
Sayers et al., 2005, USA [73]24; 46; 23:1; NA; O; 26 weeksSchizophrenia and cocaine addiction (DSM-IV); NA; CVAS: mark on a 100-mm line representing the “greatest degree of craving for cocaine since your last visit,” with endpoints marked as “NONE” and “MORE THAN EVER.”Oral olanzapine 10 mg or haloperidol 10 mg daily for 26 weeks; NAVAS: significant difference in craving over time favoring the patients in the haloperidol group42% (10); Y
Smelson et al., 2004, USA [74]35; 41; NA; Y; O; 2 weeksCocaine dependence (DSM-IV); NA; CVoris Cocaine Craving Questionnaire (VCCQ)Oral risperidone 1 mg or placebo daily for 2 weeks; NAVCCQ: significant main effect of time for the craving (F = 33.62, p = 0.01). The interaction of treatment group by time, however, was not significant for the craving8% (3); NA
Smelson et al., 2006, USA [75]31; 43; NA; NA; O; 6 weeksCocaine-dependent patients with schizophrenia (DSM-IV); NA; CVoris Cocaine Craving Questionnaire (VCCQ)Oral olanzapine 10 mg or haloperidol 10 mg daily for 6 weeks; enhancement therapy, relapse prevention, psychoeducational skills training, and a 12-step therapyVCCQ: olanzapine-treated subjects compared with those in the haloperidol group showed significantly less cue-elicited craving: Energy score (M = 39.1, SD = 9.2 vs. M = 27.6, SD = 12.8), t(16) = 2.20, p = 0.04 (2-tailed), d = 0.99, but not on the Intensity (M = 8.5, SD = 5.7 vs. M = 14.4, SD = 11.8), t(16) = 1.39, p = 0.18 (2-tailed), d = 0.6442% (13); NA
Tapp et al., 2015, USA [76]60; 48; 52:8; NA; O; 12 weeksCocaine dependence (DSM-IV); NA; CBrief Substance Craving Scale (BSCS)Oral quetiapine 400 mg or placebo daily for 12 weeks; weekly cognitive-behavioral therapy group sessionBSCS: did not differ in terms of absence of cravings (34.5% in quetiapine group versus 29.0% in placebo group; Wald statistic = 0.21, df = 1, p = 0.65)68% (41); Y
Table
Table 4. Characteristics and main findings of the studies included in the systematic review–Anticonvulsants.
Table 4. Characteristics and main findings of the studies included in the systematic review–Anticonvulsants.
Author, Year, CountryN (Sample); Age (MEAN); Gender (M:F); Search for Treatment (Y: Yes; N: No); Setting (O: Outpatient; I: Inpatient; M: Mixed); Follow-upDependence; Route of Cocaine Use (S: Smoked, I: Inhaled, IV: Intravenous, O: Oral); Cocaine Use Status (C: Current Use; A: Abstinent)Craving Assessment InstrumentPharmacotherapy and Duration; Non-Pharmacological InterventionOutcomes (AG: Active Group; PG: Control/Placebo group)Dropout %(Number); Intention to Treat (ITT) Analysis (Y: Yes; N: No)
Bisaga et al., 2006, USA [77]99; 39; 87:12; NA; O; 2 weeks single-blind placebo lead-in period + 12 weeks intervention +2 weeks lead-outCocaine dependence (DSM-IV); S, I; CSelf-reported number of days in which participants experienced cocaine cravingOral gabapentin 3200 mg or placebo daily for 12 weeks; weekly individual relapse-prevention therapyCraving: participants observed a decrease in craving frequency (z = −2.09, 0.04), but there were no significant effects of treatment or level of cocaine use51% (50); Y
Brown et al., 2012, USA [78]112; 44; 67:45; NA; O; 10 weeksCocaine dependence (DSM-IV); S, I, IV; CCocaine-Craving Questionnaire (CCQ)Oral lamotrigine 200–400 mg or placebo daily for 10 weeks; NACCQ: no differences between groups (p = 0.53)35% (42); Y
Crosby et al., 1996, USA [79]44; 34; 35:9; Y; O; 12 weeksCocaine abuse or dependence (DSM-III-R); S, I, IV; CMinnesota Cocaine Craving Scale (MCCS)Oral phenytoin 300 mg or placebo daily for 12 weeks; weekly counselingMCCS: difference did not approach significance (est = −4.96; SE = 5.69; p = 0.383)73% (32); NA
Halikas et al., 1997, USA [80]150; 33; 106:44; Y; O; 12 weeks interventionCocaine dependence (DSM-III-R); NA; CMinnesota Cocaine Craving Scale (MCCS)Oral carbamazepine 400 mg or 800 mg or placebo daily for 12 weeks; psychosocial treatment programmingMCCS: compared with placebo, the 400 mg treatment condition exhibited a reduction in intensity and duration of craving over the course of the study (est= −0.113; p< 0.001)62% (93); Y
Johnson et al., 2013, USA [81]24; 34; 19:5; N; I; 10 days intervention + 6 days experiments + 7 days intervalCocaine dependence (DSM-IV); NA; CVAS (100 mm left to right “not at all” to “extremely”)- (“crave”, “desire”, “want cocaine”, and “could refuse cocaine”)Oral topiramate 200 mg or placebo daily for 5 days followed by 3 days of cocaine IV experiments, repeated after 7 days; NABidirectional effect: wherein the effects of the highest cocaine dose (0.65 mg/kg) on VAS-Craving was decreased by topiramate, but not with low cocaine dose (0.325 mg/kg)NA; NA
Johnson et al., 2013 USA, [82]142; 44; 103:39; NA; O; 12 weeks;Cocaine dependence (DSM-IV); S, I; CBrief Substance Craving Scale (BSCS)Oral topiramate up to 300 mg or placebo daily for 12 weeks; weekly cognitive-behavioral treatmentBSCS: topiramate vs placebo were 0.499 vs 0.300 (OR, 2.33; 95% CI, 1.15–4.71; p = 0.02) for having “reportedly no craving at all” in terms of the intensity, frequency, and duration of craving in the past 24 h and 0.501 vs 0.271 (OR, 2.70; 95% CI, 1.38–5.29; p = 0.004) for having “reportedly no craving at all” in the intensity of craving on the worst day49% (70); Y
Kampman et al., 2013, USA [83]170; 44; 135:35; Y; O; 1-week baseline + 12 weeks interventionCocaine and alcohol dependence (DSM-IV); S; CMinnesota Cocaine Craving Scale (MCCS)Oral topiramate 300 mg or placebo daily for 12 weeks; weekly individual psychotherapy (CBT)MCCS: declined significantly during the trial in both groups and there were no between-group differences42% (70); Y
Reid et al., 2009, USA [84]20; 44; 16:4; NA; O; 8 days intervention + 11 days observationCocaine dependence (DSM-IV); NA; CBrief Substance Craving Scale (BSCS); VAS: with descriptors “not at all”, “mildly”, “moderately” and “extremely” equally spaced above line from 0 to 100: “how much do you desire to use cocaine right now?”Oral valproate up to 1500 mg or placebo daily for 8 days; NAVAS: “desire to use cocaine now” (F(1,38) = 3.916, p < 0.05), in which cocaine cue-induced craving levels were higher in the valproate condition. BSCS: slightly more cocaine craving (BSCS total score) in the valproate condition (F(1,38) = 2.326, p = 0.103)15% (3); NA
Somoza et al., 2013, USA [85]186; 45; 125:61; Y; O; 12 weeksCocaine dependence (DSM-IV); S, I, IV; CBrief Substance Craving Scale (BSCS)Oral vigabatrin 3 g or placebo daily for 12 weeks; weekly computerized cognitive behavioral therapy and biweekly individual counseling for 13 weeksBSCS: both groups reported less craving, but there was no significant medication effect27% (51); Y
Umbricht et al., 2014, USA [86]171; 42; 89:82; Y; O; 12 weeksCocaine dependent methadone maintenance patients (DSM-IV); NA; NACocaine Selective Severity Assessment (CSSA)Oral topiramate up to 300 mg or placebo daily + methadone treatment (median 100 mg/day); NACSSA: there was no effect of topiramate on craving scores over time34% (58); Y
Winhusen, Somoza, Ciraulo et al., 2007, USA [87]141; 42; 134: 7; Y; O; 12 weeksCocaine dependence (DSM-IV); NA; CBrief Substance Craving Scale (BSCS)Oral tiagabine 20 mg or placebo daily for 12 weeks; individual cognitive behavioral therapy on a weeklyBSCS: both groups reported significantly less craving over the course of the study, but with no significant difference between the groups as indicated by the non-significant medication by week (Z = 0.09, p > 0.05) and medication (Z = 1.68, p > 0.05) effects44% (62); NA
Table
Table 5. Characteristics and main findings of the studies included in the systematic review–Other Drugs.
Table 5. Characteristics and main findings of the studies included in the systematic review–Other Drugs.
Author, Year, CountryN (sample); Age (Mean); Gender (M:F); Search for Treatment (Y: Yes; N: No); Setting (O: Outpatient; I: Inpatient; M: Mixed); Follow-upDependence; Route of Cocaine Use (S: Smoked, I: Inhaled, IV: Intravenous, O: Oral); Cocaine Use Status (C: Current Use; A: Abstinent)Craving Assessment InstrumentPharmacotherapy and Duration; Non-Pharmacological InterventionOutcomes (AG: Active Group; PG: Control/Placebo Group)Dropout % (Number); Intention to Treat (ITT) Analysis (Y: Yes; N: No)
Becker et al., 2020, USA [88]36; 42; 28:8; Y; O; single dose + 4 weeks of observationCocaine dependence (DSM-IV); NA; CCraving Questionnaire (CCQ-10)Single dose of intravenous lidocaine 2 mg/kg immediately following a cocaine craving script (lidocaine/ craving), saline following a craving script (saline/craving), or lidocaine following a relaxation script (lidocaine/relax); weekly cognitive behavioral therapyCCQ: craving appeared higher in the lidocaine/craving and lidocaine/relax groups relative to saline/craving, but there were no significant differences between treatment groups in craving (Mean scores: Baseline: lidocaine/ craving: 31.7 (±12.6) saline/craving: 17.3 (±9.5 lidocaine/relax: 22.7 (±11.9);Endpoint: lidocaine/ craving: 32.3 (±18.5)saline/craving: 15.8 (±4.8)lidocaine/relax: 20.9 (±15.6))14% (5); NA
Bisaga et al., 2010, USA [89]81; 40; 63: 17; NA; O; 2 weeks of placebo lead-in + 12 weeks intervention + 2 weeks placeboCocaine dependence (DSM-IV); NA; CSelf-report of weekly proportion of days with cravingOral memantine 40 mg or placebo daily for 12 weeks; individual relapse-prevention therapyCraving: no changes between the two treatment groups (X2(1) = 0.41, p = 0.52) or over time (X2(1) = 0.01, p = 0.91)40% (32); Y
Brown et al., 2015, USA [90]122; 42; 82:40; NA; O; 12 weeksCocaine dependence and co-occurring bipolar I disorder (depressed or mixed mood state) (DSM-IV) S, I, IV; CCocaine Craving Questionnaire (CCQ)Oral citicoline up to 2000 mg or placebo daily for 12 weeks; therapyCCQ: no significant group or group-by-time effects were observed (Treatment group F 2.4 df 1, 108 p 0.127; treatment group by time F 1.3 df 1, 101 p 0.249)34% (44); Y
Chadwick et al., 1990, USA [91]50; 30; 25:4; NA; I; 4 weeks intervention;Cocaine dependence (DSM-III) S, I, IV; CVAS (craving scored on a 0 to 10 scale, with 0 indicating no craving and 10 indicating the worst craving ever felt)Oral L-tryptophan 1 g and L-tyrosine 1 g or placebo for 2 weeks, then 2 weeks crossed over; NAVAS: amino acids did not significantly reduce drug craving42% (21); NA
Dackis et al., 1987, USA [92]13; 28; 9:4; NA; I; 2 daysCocaine abuse (DSM-III); S, I, IV; CVAS: 100 mm scale (the right pole indicating maximal craving, and the left pole indicating no craving)Single dose of bromocriptine 1,25 mg or placebo; NAVAS: the mean (± SD) R value after bromocriptine (16.2 ± 14.7) was significantly greater (t = 1.84, df= 12, p < 0.05) than after placebo (10.2 ± 13.0)NA; NA
Dakwar, Levin et al., 2014, USA [93]11; 47; 7:1; N; I; 9 days intervention+ 4 weeks observationCocaine dependence (DSM-IV); S; CVAS: 100 mm scale corresponding to the intensity of their wanting cocaine, from “none at all” on the left to “extremely” on the rightIntravenous ketamine (0.41 mg/kg or 0.71 mg/kg), administered at three doses, during 52-min or lorazepam 2 mg, separated by 48 h; 10-min mindfulness-based exerciseVAS: reduction in cue-induced craving (p = 0.012) in ketamine group relative to lorazepam group27% (3); N
Dakwar, Anerella et al., 2014, USA [94]8; 48; NA; N; I; 9 days intervention + 4 weeks observationCocaine dependence (DSM-IV); S; CVAS: 100 mm scale corresponding to the intensity of their wanting cocaine, from “none at all” on the left to “extremely” on the rightIntravenous ketamine (0.41 mg/kg or 0.71 mg/kg), administered at three doses, during 52-min or intravenous lorazepam 2 mg, separated by 48 h; NAVAS: mystical-type effects did not mediate cue-induced craving0; NA
Dakwar et al., 2017, USA [95]20; 49; 11:9; N; I; 3 days intervention + 7 weeks observationCocaine dependence (DSM-IV); NA; NAVASIntravenous ketamine (0.71 mg kg−1), administered at three doses over 6 days or of the active control midazolam (0.025 mg kg); NAVAS: craving significantly reduced initially but not throughout the monitoring period; ketamine led to significant craving reduction (%) prior to discharge (59.6 vs 15.3%, t17 df = 3.44, p < 0.01) but not at subsequent time-pointsNA; NA
Dieckmann et al., 2014, Brazil [96]111; 32; 111:0; NA; O; 8 weeksCocaine dependence (DSM-IV); S, I; CMinnesota Cocaine Craving Scale (MCCS)Oral biperiden 6 mg or placebo daily for 8 weeks; brief cognitive-behavioral psychotherapyMCCS: reduction of 19.1% of craving in the placebo group (p = 0.017) and 37.6% in the biperiden group (p<0.001)69% (77); Y
Eiler et al., 1995, USA [97]63; 36; 63:0; Y; I; 18 days interventionCocaine dependence (DSM-III); S, I, IV; CVAS: a single horizontal line which represents craving for cocaine on a continuum, starting with 0, representing no cocaine craving, up to 10, which represents the highest degree of cocaine cravingOral bromocriptine up to 10 mg or placebo daily for 18 days; NAVAS: time effect F = 3.46, p < 0.001; first week: time effect F = 3.84, p < 0.002). Bromocriptine did not seem to reduce cocaine craving more expeditiously or quantitatively than placebo.53% (34); NA
Elkashef et al., 2006, USA [98]300; 41; 234:66; Y; O; 2 weeks baseline+ 8 weeks interventionCocaine dependence (DSM-IV); S, I; CBrief Substance Craving Scale (BSCS)Selegiline Transdermal System (STS) 6 mg or placebo (PBO) patches daily for 8 weeks; individual psychotherapy weeklyBSCS: difference between the selegiline and placebo groups was not significant (p = 0.96): Mean weekly scores: baseline: PBO: 6.7 (2.7), STS: 6.5 (2.5); endpoint: PBO: 4.1 (3.0), STS: 4.5 (3.0)31% (93); NA
Fox et al., 2012, USA [99]29; 39; 19:10; Y; I; 4 weeksCocaine dependence (DSM-IV); NA; CVAS: intensity of your desire to use cocaine/nicotine at the moment, in which 1 = ‘not at all’ and 10 = ‘extremely high’Oral guanfacine up to 3 mg or placebo daily for 4 weeks; group drug counselingVAS: guanfacine significantly decreased cue-related cocaine cravingNA; NA
Fox et al., 2013, USA [100]42; 42; 24:18; Y; I; 1-week baseline + 1-week intervention + 2 weeks observationCocaine dependence (DSM-IV); NA; CCocaine Craving Questionnaire-Brief (CCQ)Oral progesterone 400 mg or placebo daily for 7 days; 12-Step based Group Drug Counseling ManualCCQ: progesterone group significantly presented lower levels of cocaine craving compared with placebo (p < 0.05) in both males and femalesNA; NA
Handelsman et al., 1995, USA [101]59; 36; 59:0; NA; O; 1-week single blind placebo+ 8 weeks interventionCocaine dependence in methadone-maintained treatment (DSM-IIIR); NA; CVAS: average craving and peak craving for each day scored from zero (not at all) to ten (most ever)Oral amantadine 200 mg or and 400 mg or placebo daily for 8 weeks; NAVAS: no difference across medication groups for craving, but there was a reduction overall over time13% (8); NA
Handelsman et al., 1997, USA [102]50; 38; 50:0; Y; O; 5 weeks intervention + 3-month psychotherapy;Cocaine dependence in methadone-maintained treatment (DSM-III-R-); NA; CCocaine Craving Questionnaires (CCQ); VAS (the average daily craving and perceived resistance to using cocaine, assessed by the use of aloo-mm, non-numerated visual analog scale anchored from 0 (not at all) to 100 (most ever))Oral bromocriptine 2,5 mg or placebo daily for 5 weeks; cognitive behavioral therapyCCQ and VAS: bromocriptine group did not differ from the placebo group in craving for cocaine20% (10); NA
Jobes et al., 2011, USA [103]59; 41; 50:9; N; O; 1 daySelf-report of using cocaine for at least 1 year and at least once in the previous 30 days; S, I; CCocaine Craving Questionnaire (CCQ); VAS (questions worded, respectively, “Right now, how much do you [crave/want/need] cocaine?”)Single dose of oral clonidine 0.1 or 0.2 mg or placebo; NAVAS: in the placebo group, Crave Cocaine was significantly increased from baseline after both the stress script and the drug-cue script, but not after the neutral script; in the 0.1-mg group, Crave Cocaine increased only after the drug-cue script, not the stress script; in the 0.2-mg group, Crave Cocaine did not increase after either active script. No significant effects on the VAS measure Need cocaine; CCQ: there was also a significant effect of clonidine dose, with a dose-related decrease in craving scores [F(2,56) = 5.49, p = 0.007]0; NA
Jobes et al.; 2015; USA [104]35; 42; 16:17; NA; M; 6 weeksCocaine-abusing outpatients who were also being maintained on methadone for heroin dependence; NA; CCocaine Craving Questionnaire (CCQ), VAS (was worded “Please rate the intensity of your desire to use cocaine AT THIS MOMENT”);Intravenous propranolol 40 mg or dextrose placebo intravenously (3 interventions, 1 dose in each); NAVAS: propranolol acutely increased reactivity to the cocaine; CCQ: increased scores in the propranolol group only7% (2); N
Johnson et al., 2004, USA [105]18; 33; 12:6; N; O; 4 weeksCocaine dependence (DSM-IV); NA; NAVASOral isradipine 15 or 30 mg or placebo; plus cocaine HCl 0.325 or 0.650 mg/kg or placebo, for 9 sessions separated by a 2-day interval; NAVAS: no main isradipine effect in cravingNA; NA
Johnson et al., 2019, USA [106]39; 51; 27:12; Y; O; 2 weeks of induction phase+ 3 weeks of intervention+ 2 weeks observationCocaine dependence (DSM-IV); I; NACocaine Craving Questionnaire-Now (CCQ)Oral D-cycloserine (DCS) 50 mg or placebo daily for 3 weeks; Contingency management (CM) interventionCCQ: craving decreased for both groups following the introduction of CM and then for the DCS group, increased significantly during the posttreatment phase (post hoc pairwise comparison, p 0.01)21% (11); N
Kablinger et al., 2012, USA [107]26; 42; 17:9; Y; O; 6 weeks of interventions + 2 weeks of observationsCocaine dependence (DSM-IV); NA; CCocaine Craving Questionnaire (CCQ)Oral metyrapone/ oxazepam 500/20 mg or 1500/20 mg or placebo daily for 6 weeks; NACCQ: a change from baseline to endpoint did not reach statistical significance for the pooled group compared with placebo, but reached statistically significance in some visits51% (23); NA
Kampman et al., 2001, USA [108]108; 36; 88:20; Y; O; 1-week placebo lead in + 8-week interventionCocaine dependence (DSM-IV); S, I, IV; CVASOral propranolol up to 100 mg or placebo daily for 8 weeks; twice-weekly individual cognitive-behavioralVAS: decline in cocaine craving during the trial (Wald x2= 24.0, p = 0.001) but there was no significant medication group by time interaction (Wald x2 = 7.4, p = 0.387)47% (51); NA
Kampman et al., 2006, USA [109]199; 41; 130:69; Y; O; 2-week baseline phase + 8-weeks of interventionCocaine dependence (DSM-IV); S, I, IV; CBrief substance craving scale (BSCS)Oral amantadine 300 mg or propranolol 100 mg or combination of amantadine 300 mg + propranolol 100 daily or placebo for 8 weeks; twice-weekly individual cognitive-behavioral therapyBSCS: significant decline over the trial in all groups but there were no significant group effects or group by time interactions41% (82); Y
Kampman et al., 2010, USA [108]60; 45; 45:15; Y; O; 1-week baseline + 8 weeks interventionCocaine dependence (DSM-IV); S, I; C;Brief Substance Craving Scale (BSCS)Oral acamprosate 666 mg 3 times daily or placebo for 8 weeks; weekly individual cognitive behavioral relapse prevention therapyBSCS: cocaine craving showed a significant decline over the trial in both groups (F = 19.89, p < 0.001), with no difference between groups40% (24); NA
Larowe et al., 2013, USA [110]126; 43; 83:28; Y; O; 8 weeks;Cocaine dependence (DSM-IV); S; C;Brief Substance Craving Scale (BSCS);Oral N-acetylcysteine 1200 mg, 2400 mg or placebo daily for 8 weeks; weekly session of manual-based cognitive therapy. BSCS: time-related reduction, Wald χ2= 104.1, df = 8, p< 0.001; no difference between groups (among abstinent participants, NAC presented significant less craving rates)44% (55); N
Lee at. Al., 2015, USA [111]23; 38; 22:1; NA; I; 1 weekCocaine dependence (DSM-IV); S; A(VAS): “If your drug of choice was in front of you right now, what’s the likelihood that you would use?”Intranasal oxytocin (OT) 24 IU or placebo, for 4 sessions; NAVAS: the effect of OT on desire to use before exposure to cues was small (mean ± SE: OT = 2.57 ± 0.39; PL = 1.91 ± 0.39) but significant (df = 1,22; F = 5.22, p = 0.032), where desire to use was augmented under OTNA; NA
Leyton et al., 2005, USA [112]8; NA; 8:0; N; M; 3 daysNondependent, regular cocaine users (DSM-IV); NA; CVAS items: want cocaine, crave cocaine, urge for cocaine, and desire cocaine −1 (least) and 10 (most)Balanced amino acid mixture or acute phenylalanine–tyrosine depletion (APTD), followed by L-dopa/carbidopa (2 × 100 mg/25 mg) or placebo; NAVAS: cue- and cocaine-induced craving was significantly reduced by APTD and APTD + L-dopa, for the following: want cocaine, F(10, 70) = 3.27, p < 0.002; urge for cocaine, F(10, 70) = 2.10, p < 0.04; and the total craving score, F(10, 70) = 2.25, p < 0.0250; NA
Licata et al., 2011, USA [113]29; 38; 18:11; N; O; 8 weeks intervention + 4 weeks observationCocaine dependence (DSM-IV); S, I; CVAS: ranged from 0 ‘none at all’ to 10 ‘extremely high’ of their desire to use cocaineOral citicoline 1000 mg or placebo daily for 8 weeks; weekly group therapyCocaine craving decreased during the treatment period for both treatment groups, but not significantly38% (11); NA
Malcolm et al., 2000, USA [114]358; NA; 282:76; Y; O; 12 weeks intervention + 4 months follow up visitsCocaine dependence and combined cocaine/alcohol dependence (DSM-III-R); NA; CVASOral pergolide 0.10 or 0.50 mg or placebo for 12 weeks; 12-step based group therapiesVAS: Although craving scores rose considerably over the first week of the study (range 40–50 mm), scores did not differ for any of the 12-week visits for any of the treatment groups66% (202); Y
Malcolm et al., 2005, USA [115]116; 36; 89:27; NA; O; 12 weeksCocaine dependence (DSM-IV); S, IV; CUnclearOral amlodipine 5–10 mg or placebo daily for 12 weeks; 12 standard manual-driven cognitive behavioral therapy sessionsCraving score did not differ significantly between treatment arms81% (90); NA
Meneses-Gaya et al., 2020, Brazil [116]31; 32,9; 31:0; NA; I; 10 daysDSM-IV diagnosis of crack-cocaine dependence;Cocaine Craving Questionnaire–Brief (CCQ-Brief); Minnesota Cocaine Craving Scale (MCCS);Oral canabidiol (CBD) 300 mg or placebo daily for 10 days; group psychotherapy once a weekCCQ-Brief: significant effect of time (F10,230 = 16.174; p < 0.001), but not
of treatment (F10,230 = 2.663; p = 0.116) or time/treatment interaction (F10,230 = 0.489; p = 0.897).MCCS: significant effect of time (F10,230 = 16.450;
p < 0.001), but not of treatment (F10,230 = 2460		19% (6); Y
Milivojevic et al., 2016, USA [117]46; 41; 29:17; Y; I; 1 weekCocaine dependence (DSM-IV); NA; CCocaine Craving Questionnaire-Brief (CCQ)Oral micronized progesterone 400 mg or placebo daily for 7 days; NACCQ: active group had significantly lower post-imagery cocaine cravingNA; NA
Modesto-Lowe, 1997, USA [118]26; 36; 23:3; Y; O; 8 weeksComorbid alcohol and cocaine abuse/ dependence (DSM-IV); NA; NAVAS: 5- point rating scale that range from ‘none at all’ to ‘extremely’-(‘How strong is your desire for cocaine right now?’); Cocaine Craving Questionnaire (CCQ)Oral naltrexone 50 mg or placebo daily for 8 weeks; NAVAS/CCQ: there was no effect of medication on the desire for cocaineNA; NA
Mongeau-Pérusse et al., 2021, Canada [119]78; 45,9; 64:14; NA; M; 12 weeksDSM 5 criteria for cocaine use disorder; S, I and IV; AVAS:ranging from 0 to 10; Cocaine Craving Questionnaire-Brief (CCQ-Brief); Cocaine Selective Severity Assessment (CSSA)Oral cannabidiol (CBD) 800 mg or placebo daily for 12 weeks after 10 days of inpatient detoxification; relapse prevention group sessionVAS, CCQ, CSSA: CBD did not reduce cocaine craving37% (28); NA
Mooney et al., 2006, USA [120]S1: 67, S2:122; S1:35, S2:39; S1: 45:22, S2: 103:19; NA; O; S1: 5 weeks, S2: 9 weeksCocaine users (DSM-IV); S; CS1: VAS S2: Cocaine subscale of the Brief Substance Craving Scale (BSCS)S1: L-dopa/carbidopa 800/200 mg or placebo daily for 5 weeks; supportive behavioral counseling; S2: L-dopa/carbidopa 800/200 mg or 1600/400 mg or placebo daily for 9 weeks; supportive behavioral counselingS1: Craving: no differences between groups; S2: Craving: no differences between groupsS1: 62% (45), YS2: 57% (70); Y
Moran-Santa Maria et al., 2015, USA [121]84; 41; 71:13; N; M; 3 daysCocaine dependence (DSM-IV); NA; CCocaine Craving Questionnaire (CCQ)Single dose of oral guanfacine 2 mg or placebo; NACCQ: participants in the no-stress group reported significantly greater craving in response to the cocaine-cue as compared to the neutral cue (p < 0.001), in both the no-stress guanfacine (p < 0.001) and no-stress placebo (p = 0.023) groups. In the stress group, participants in both the guanfacine and placebo groups reported similar craving ratings in response to the cocaine and the neutral cue (p = 0.480)NA; Y
Nann-Vernotica et al., 2001, USA [122]10; 38; 9:1; N; I; 1 weekCocaine dependence (DSM-IV); S, IV; CVAS: “how much do you desire cocaine?”Four doses of oral ecopipam or placebo (0, 10, 25, and 100 mg) daily for 1 week; NAVAS: Ecopipam largely failed to alter the desire for cocaineNA; NA
Nasser et al., 2014, USA [123]29; 40; 23:6; N; NA; 1-day intervention + 6 days observationCocaine abuse (DSM-IV); NA; CBrief substance craving scale (BSCS); VASSingle dose RBP-8000 (100 or 200 mg) or placebo; NABSCS: results were low and fairly steady over the entire assessment period; VAS: results were similar over the entire assessment period and across treatment groups10% (3); NA
Newton at. Al., 2015, USA [124]18; 40; 11:7; N; I; 15 daysCocaine dependence (DSM-IV-TR); S, IV; NAVAS: participants rated “DESIRE” cocaine, anchored at 0 (not at all) and 100 (most ever)Oral pramipexole up to 3.0 mg or placebo daily for 15 days; NAVAS: No significant main effects was found for “DESIRE”0; Y
Petrakis et al., 2000, USA [125]67; NA; 32:35; NA; O; 12 weeksCocaine dependence in methadone-maintained opioid-dependent (DSM-IIIR); S, I, IV; CSelf-report cocaine cravingOral disulfiram 250 mg or placebo daily, was placed directly in the methadone for 12 weeks; weekly individual and group counselingThere was a significant decrease in craving over time for the entire sample (Z 5 9.05; p, 0.01), but no significant decrease in craving by treatment group23% (13)
Plebani et al., 2012, USA [126]37; NA; 27:10; Y; O; 1-week baseline + 8 weeks interventioncocaine dependence (DSM-IV); NA; CBrief Substance Craving Scale (BSCS); Cocaine Selective Severity Assessment (CSSA)Oral varenicline 2 mg or placebo daily for 8 weeks; manual-guided cognitive behavioral therapyBSCS: craving showed a significant decline over the trial in both groups (F = 20.34, p < 0.001); CSSA: both varenicline and placebo-treated groups show significant decreases in craving from baseline to end of study (p = 0.004)NA; NA
Preston et al., 1993, USA [127]18; 33; 18:0; N; I; 5 weekscocaine abusers/dependent (DSM-III); IV; CVAS: rated ‘Desire for Cocaine’ by placing a mark along a 100-mm line marked at either end with none and extremelyIntravenous cocaine (0, 12.5, 25 and 50 mg) was administered 2 h after oral mazindol (0, 1 and 2 mg), 2 times per week for 5 weeks; NAVAS: there were no significant main effects of mazindol alone and no significant mazindol/cocaine interactions on any scales on the VAS55% (10); N
Price et al., 2012, USA [128]32; 44; 22:10; Y,N; O; 3 days of intervention + 12 days observationCocaine dependence(DSM-IV); NA; CVASOral D-cycloserine 50 mg (DCS) only or D-cycloserine 50 mg +placebo (DSC-PBO) or placebo (PBO), for 3 sessions; NAVAS: while baseline craving was not significantly different between groups at the beginning of session one, the session two baseline craving was significantly higher in the DCS-only group as compared to the PBO group and the session three baseline craving was significantly higher in the DCS-only group as compared to both the PBO and the DCS–PBO groupsNA; NA
Prisciandaro et al., 2013, USA [129]25; 45; 23:2; NA; O; 2 weeksCocaine dependence (DSM-IV); ATimeline Follow-back (TLFB): participants were asked to rate their craving, from zero (“none”) to four (“severe”)Oral D-cycloserine (DCS) 50 mg or placebo for 2 sessions; two sessions of cocaine cue exposure and skills trainingTLFB: there was no significant interaction between medication group and MRI session (p = 0.13; placebo participants’ craving from pre-scan to post-scan: Cohen’s d = −0.37; DCS participants’ craving from pre-scan to post-scan: Cohen’s d = 0.47).18% (4); NA
Reid et al., 1998, USA [126]20; NA; 18:2; NA; I; 2 daysSelf-report patients with a history of smoking crack cocaine and cigarette smokers; S; CVAS: a 1–100 mm scale demarcated craving at 25 mm intervals with the adjectives: not at all; mildly; moderately; and extremelySingle dose of transdermal nicotine 44 mg or placebo; NAVAS: the cue-induced increase in cocaine craving was strongly enhanced by nicotineNA; NA
Reid et al., 1999, USA [85]23; 41; 20:3; NA; O; 2 daysCocaine dependence (DSM-IV); S; CVAS: cocaine craving and desire to use cocaine nowSingle dose of oral mecamylamine 2.5 mg or placebo; NAVAS: cue-induced cocaine craving and desire to use cocaine now were significantly lower during the mecamylamine conditionNA; NA
Reid, Angrist et al., 2005, USA [130]23; 45; 18:5; NA; O; 8 weeksCocaine dependence (DSM-IV); S, I; CBrief Substance Craving Scale (BSCS)Oral celecoxib 200 mg (CLX) or placebo (PBO) daily for 8 weeks; individual cognitive behavioral counselingBSCS: moderate decrease in craving when comparing baseline with last study visit. However, the change was not significantly different between celecoxib and placebo groups (Baseline CLX 6.3 ± 2.8, PBO 6.6 ± 2.6; End-point CLX 4.2 ± 2.3, PBO 5.4 ± 2.8 p= 0.686);48% (11); NA
Reid et al., 2005, USA [131]35; NA; NA; NA; O; 8 weeks of placebo + 16 week of active interventionMethadone maintained subjects and cocaine dependence (DSM-IV); NA; CBrief Substance Craving Scale (BSCS)Transdermal mecamylamine 6 mg/ or placebo daily for 16 weeks; NABSCS: Cocaine craving showed moderate improvement in both groups, with a significantly greater reduction in cocaine craving (p < 0.05) in the placebo group20% (7); Y
Renshaw et al., 1999, USA [132]14; 37; 11:3; NA; O; 2 weeksCocaine dependence (DSM-IV); NA; C, AVAS: How strong is your desire not to use cocaine right now? How strong is your urge for cocaine right now? CCQ (Cocaine Craving Questionnaire)Oral citicoline 500 mg or placebo daily for 14 days; NACCQ: results revealed a group × condition interaction on the CCQ category, “Lack of control over use” (F1,8 = 6.02, p = 0.040), with citicoline treatment group reporting a decrease in “Lack of control over use” from pre- to post-treatments. There were no other significant differences in other measures; VAS: placebo group reported greater “Urge for cocaine” than the citicoline group at the post-treatment session, both prior to and following presentation of the crack cocaine cue video (F1,9 = 10.91, p = 0.01, and F1,9 = 16.62, p = 0.002, respectively). A main effect for condition “Desire to use cocaine right now” (F1,8 = 5.57, p = 0.046) was revealed, with subjects reporting a greater desire to use cocaine pre-treatment as compared to post-treatment, regardless of treatment or video presented.NA; NA
Rosse et al., 1994, USA [133]66; 33; 66:0; NA; I; 3 weeksCocaine dependence (DSM-III); NA; CQuestionnaires of cocaine craving and urges (QCU); VAS: rate craving from 0 (none) to 3 (severe)Oral nimodipine (NDP) 90 mg or placebo (PBO) daily for 21 days; intensive 12-step milieu-oriented psychosocial therapy 4 h/dayQCU: significant decreases for all items, but no difference between groups (Baseline (Mean (SD): PBO: 64,8 (32,3), NDP: 60,4 (34,7) Endpoint: PBO: 44,8 (35,0), NDP: 47,3 (40,9)); VAS: craving was not significantly altered by the intervention (Baseline (Mean0–3): PBO: 0,62, NDP: 0,48; Endpoint: PBO: 0,50, NDP: 0,46)NA; NA
Saladin et al., 2013, USA [134]50; 40; 33:17; NA; I; 2 days of procedure + 1-week observationCocaine dependence (DSM-IV); S; CCraving/Distress/Mood States Scale (CDMS): 100 mm visual analogue scales (VAS), with each being anchored by the adjectival modifiers “not at all” (left side of scale) and “extremely” (right side of the scale). The craving item asked participants to rate the desire to use cocaine “right now”Single oral dose of propranolol 40 mg or placebo; NAVAS After 24 h: propranolol treated group would evidence significantly lower cue-elicited cocaine craving and reactivity relative to the placebo treated group; after 1 week: craving was lower in the propranolol group, but this difference did not exceed threshold for significance/trend. Propranolol group evidenced significantly lower mean craving than the placebo group (F1,47 = 4.98, p = 0.03)NA; NA
Santa Ana et al., 2015, USA [135]47; 47; 40:7; NA; O; 1 weekCocaine dependence (DSM- IV); NA; CVAS: Craving was assessed by ‘do you crave cocaine? (from ‘0′ = “not at all” -‘10′ = “extremely”) of subjective desire to use cocaine2 sessions of D-cycloserine 50 mg or placebo, with 1-week interval; NAVAS: craving scores declined in both treatment conditions with differences becoming statistically significant from baseline2% (1); NA
Schmitz et al., 2017, USA [136]30; 48; 22:8; Y; O; 12 weeksCocaine dependence (DSM-IV); NA; NABrief Substance Craving Scale (BSCS); VAS: consisting of 100 mm line, anchored by 0 “not at all” and 100 “extremely,” for cocaine craving right now, craving on average in the past week, and the worst craving in the past weekOral pioglitazone (PIO) 45 mg or placebo (PBO) daily for 12 weeks; weekly cognitive-behavioral therapy and prize-based contingency management for attendanceBSCS: reduced by a factor of 0.24 for participants receiving PIO compared to 0.09 for participants receiving PBO; VAS: decrease in craving by a factor of 3.84 for PIO versus 1.34 for PBO40% (12); Y
Schmitz et al., 2001, USA [137]85; 34; 62:23; NA; O; 12 weeks of intervention + 1-week observationCocaine dependence (DSM-IV); NA; NACocaine Craving Scale (CCS)Oral naltrexone 50 mg or placebo daily for 12 weeks; relapse prevention (RP) therapy or drug counselingCCS: no differences on craving as a function of time, therapy, or medication. overall mean craving scores were lower at posttreatment (M= 16,1; SD = 24,3) than at intake (M = 29,7; SD = 32,3), consistent with a significant effect of time, F(2;37) = 3,57; p = 0,0351% (43); Y
Schmitz et al., 2008, USA [138]161; 41; 134:27; Y; O; 12 weekCocaine dependence (DSM-IV); NA; CBrief Substance Craving Scale (BSCS)Oral sustained release levodopa/carbidopa 800/200 mg daily or placebo for 12 weeks; Clinical Management (ClinMan); ClinMan + Cognitive Behavioral Therapy (CBT); or ClinMan + CBT + Voucher-Based Reinforcement Therapy (VBRT)BSCS: those receiving levodopa reported significantly lower craving scores (levodopa, M = 2.8, SE = 0.30; placebo, M = 3.7, SE = 0.31)59% (95); Y
Schulte et al., 2018, Netherlands [139]38; 18–55; 38:0; Y; O; 25 daysCocaine use disorder (DSM-5); I; NAQuestionnaire for Cocaine Urges (QCU); Obsessive Compulsive Drug Use Scale (OCDUS); Desire for Drug Questionnaire (DDQ); VAS: ranging from 1 to 10 on which participants had to indicate their cravingOral N-acetylcysteine (NAC) 2400 mg or placebo daily for 25 days; Working memory (WM) training onlineLaboratory assessment: more positive effects of WM-sessions for the NAC group (B = 0.44 (0.10), p= 0.005) on craving, than for the placebo group (B= 0.04 (0.13), p =0.73). Ecological momentary assessment: no significant effects on craving of the treatment.37% (14); N
Shoptaw et al., 2002, USA [140]69; 36; 55:14; Y; O; 2 weeks screening +16 weeks intervention + brief follow up after 9 months of interventionCocaine dependence (DSM-IV); S, I, O; NAVAS: (0‘not at all’ to 100‘strongest ever’) that asked participants to mark on a 100 mm line indicating their ‘‘most intense craving for cocaine that occurred at any time during the past 24 h’’Oral amantadine hydrochloride 200 mg or placebo daily for 16 weeks; three times weekly, 90-min Matrix Model cocaine counseling sessionsVAS: placebo group reported craving levels at baseline that were almost two times greater than in amantadine group. This proportionate difference between conditions was maintained to treatment termination with a statistically significant effect of medication condition on craving ratings (F(1,64) = 7.27, p < 0.001) after including baseline ratings as covariates78% (15); NA
Shoptaw et al., 2003, USA [141]70; 35; 48:22; Y; O; 16 weeksCocaine dependence (DSM-IV); S, I, IV, O; CVAS: “most intense craving for cocaine that occurred at any time during the past 24 h”Oral baclofen 60 mg or placebo daily for 16 weeks; thrice-weekly cognitive-behavioral drug counseling groupsVAS: no statistically significant difference between participants76% (53); NA
Winhusen et al., 2005, USA [100]15; 40; NA; N; I; 2 days intervention+ 2 days observationCocaine dependence (DSM-IV); S, IV; CVAS: 0–100 of desire for drugOral metyrapone 750 mg or placebo and infusion (40 mg of cocaine or saline) for 2 days; NAVAS: the stress and conditioned craving procedures did not significantly alter participants’ VAS ratings; thus, the potential effects of metyrapone on stress- and cue-induced craving could not be evaluated20% (3); NA
Winhusen, Somoza, Sarid-Segal et al., 2007, USA [142]119; 41; 84:35; Y; O; 12 weeksCocaine dependence (DSM-IV); S, I; CBrief Substance Craving Scale (BSCS)Oral reserpine 0.5 mg or placebo daily for 12 weeks; weekly individual cognitive behavioral therapyBSCS: both groups reported significantly less craving over the course of the study, but there was no significant difference between the groups as indicated by the non-significant Medication by Week (Z = −1.15, p > 0.05) and Medication (Z = −0.32, p > 0.05) effects34% (40); NA
Woodcock et al., 2021, USA [143]12; 48; 11:1; N; I; 2 weeksCocaine use (self report); S; CCocaine Craving Questionnaire (CCQ)N-acetylcysteine 3600 mg or placebo daily for 1 week and then crossed over for 1 more week; NACCQ: no impact in craving0; N
S1: study 1; S2: study 2.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Lassi, D.L.S.; Malbergier, A.; Negrão, A.B.; Florio, L.; De Aquino, J.P.; Castaldelli-Maia, J.M. Pharmacological Treatments for Cocaine Craving: What Is the Way Forward? A Systematic Review. Brain Sci. 2022, 12, 1546. https://doi.org/10.3390/brainsci12111546

AMA Style

Lassi DLS, Malbergier A, Negrão AB, Florio L, De Aquino JP, Castaldelli-Maia JM. Pharmacological Treatments for Cocaine Craving: What Is the Way Forward? A Systematic Review. Brain Sciences. 2022; 12(11):1546. https://doi.org/10.3390/brainsci12111546

Chicago/Turabian Style

Lassi, Dângela Layne Silva, André Malbergier, André Brooking Negrão, Lígia Florio, João P. De Aquino, and João Maurício Castaldelli-Maia. 2022. "Pharmacological Treatments for Cocaine Craving: What Is the Way Forward? A Systematic Review" Brain Sciences 12, no. 11: 1546. https://doi.org/10.3390/brainsci12111546

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop